Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1aCondition 1bCondition 1cCondition 2aCondition 2bCondition 3aCondition 3bCondition 4Condition 5aCondition 5bCondition 6
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.spleen massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000171spleen wet weight0.708g0.03260.073MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76115vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood total protein amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000661serum total protein level9.38g/dl0.66951.497MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76125vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood cholesterol amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000363serum total cholesterol level68.12mg/dl6.42214.36MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76130vehicle control condition (for 91 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney superoxide dismutase activityRS:0001014Hsd:WImale0 days6CMO:0002229kidney superoxide dismutase activity to total protein level ratio13.53U/mg0.80421.97MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days)76187vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney superoxide dismutase activityRS:0001014Hsd:WImale0 days6CMO:0002229kidney superoxide dismutase activity to total protein level ratio8.13U/mg0.7921.94MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76188vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.body massRS:0002943BluHsd:LEmale70 days8CMO:0000012body weight353.1g10.830.547MMO:0000016body weighing method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)75955vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.eating behavior traitRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0002178total food calorie intake rate2995.2kcal/d187.0528.9159MMO:0000160unspecified method0.0controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76182controlled in utero environment (for 9 days)vehicle control condition (for 30 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.eating behavior traitRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0002209food calorie intake level to change in body weight ratio10.1kcal/g0.30.8485MMO:0000160unspecified method0.0controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days)76204controlled in utero environment (for 9 days)vehicle control condition (for 30 days)maternal milk (for 21 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.catalase activityRS:0001014Hsd:WImale0 days6CMO:0002224kidney catalase activity to total protein level ratio35.98nmol/mg0.80831.98MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days)76234vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.catalase activityRS:0001014Hsd:WImale0 days6CMO:0002224kidney catalase activity to total protein level ratio21.73nmol/mg0.61651.51MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76235vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.eating behavior traitRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0002212food intake weight to change in body weight ratio6.7g/g0.30.8485MMO:0000160unspecified method0.0controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days)76203controlled in utero environment (for 9 days)vehicle control condition (for 30 days)maternal milk (for 21 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.body massRS:0001014Hsd:WImale0 days6CMO:0000012body weight140.6g0.53071.3MMO:0000016body weighing method0.0vehicle control condition (for 10 days)75951vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.body massRS:0001014Hsd:WImale0 days6CMO:0000012body weight137.6g0.44911.1MMO:0000016body weighing method0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75952vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.body massRS:0002943BluHsd:LEmale98 days8CMO:0000012body weight457.7g15.944.972MMO:0000016body weighing method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)75962vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.urine outputRS:0001014Hsd:WImale0 days6CMO:0000260timed urine volume6.8ml/d0.61241.5MMO:0000357urine volume measurement method0.0vehicle control condition (for 10 days)75965vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.urine outputRS:0001014Hsd:WImale0 days6CMO:0000260timed urine volume21.8ml/d1.30643.2MMO:0000357urine volume measurement method0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75966vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.body massRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0000420body weight gain104.6g5.916.6877MMO:0000016body weighing method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)75969vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.blood creatinine amountRS:0001014Hsd:WImale0 days6CMO:0000057serum creatinine level0.54mg/dl0.01220.03MMO:0000271serum creatinine analysis0.0vehicle control condition (for 10 days)75972vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.blood creatinine amountRS:0001014Hsd:WImale0 days6CMO:0000057serum creatinine level1.69mg/dl0.05720.14MMO:0000271serum creatinine analysis0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75973vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.blood urea nitrogen amountRS:0001014Hsd:WImale0 days6CMO:0000587serum urea nitrogen level69.64mg/dl2.49856.12MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days)75976vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.blood urea nitrogen amountRS:0001014Hsd:WImale0 days6CMO:0000587serum urea nitrogen level96.11mg/dl1.91474.69MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75977vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.body massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000012body weight388g16.815237.6MMO:0000016body weighing method0.0vehicle control condition (for 91 days)76041vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.body massRS:0001014Hsd:WImale126 days to 119 days5CMO:0002216change in body weight to body weight ratio255%13.416430.0MMO:0000016body weighing method0.0vehicle control condition (for 91 days)76065vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.kidney massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000082right kidney wet weight1.214g0.03710.083MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76070vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.kidney massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000083left kidney wet weight1.192g0.05630.126MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76075vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.kidney massRS:0001014Hsd:WImale126 days to 119 days5CMO:0001953right kidney wet weight to body weight ratio3.138mg/g0.0590.132MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76080vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.kidney massRS:0001014Hsd:WImale126 days to 119 days5CMO:0001954left kidney wet weight to body weight ratio3.072mg/g0.07110.159MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76085vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.liver massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000158liver wet weight13.6g1.04652.34MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76090vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.liver massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000633liver weight to body weight ratio34.846g/kg1.20932.704MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76095vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.spleen massRS:0001014Hsd:WImale126 days to 119 days5CMO:0000149spleen weight to body weight ratio0.1832%0.00840.0188MMO:0000005post excision weight measurement0.0vehicle control condition (for 91 days)76120vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood triglyceride amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000360serum triglyceride level156.94mg/dl14.930733.386MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76135vehicle control condition (for 91 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.body massRS:0002943BluHsd:LEmale70 days8CMO:0000012body weight345.8g13.137.0524MMO:0000016body weighing method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)76140vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood calcium amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000503serum calcium level12.82mg/dl0.23750.531MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76141vehicle control condition (for 91 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.body massRS:0002943BluHsd:LEmale98 days8CMO:0000012body weight491.1g20.457.6999MMO:0000016body weighing method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76148vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood albumin amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000550serum albumin level0.04486g/dl0.00160.0036MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76149vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood bilirubin amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000376serum total bilirubin level0.96mg/dl0.07470.167MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76156vehicle control condition (for 91 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.body massRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0000420body weight gain145.3g9.326.3044MMO:0000016body weighing method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76161vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood urea nitrogen amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000587serum urea nitrogen level77.76mg/dl3.17977.11MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76164vehicle control condition (for 91 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.eating behavior traitRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0002178total food calorie intake rate2103.7kcal/d62.9177.9081MMO:0000160unspecified method0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)76169vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood creatinine amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000057serum creatinine level0.68mg/dl0.04920.11MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76170vehicle control condition (for 91 days)
1545Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.blood lactate dehydrogenase amountRS:0001014Hsd:WImale126 days to 119 days5CMO:0000668serum lactate dehydrogenase activity level1068U/l313.2284700.4MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 91 days)76177vehicle control condition (for 91 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney glutathione peroxidase activityRS:0001014Hsd:WImale0 days6CMO:0002227kidney glutathione peroxidase activity to total protein level ratio22.63U/mg1.34723.3MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days)76191vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney glutathione peroxidase activityRS:0001014Hsd:WImale0 days6CMO:0002227kidney glutathione peroxidase activity to total protein level ratio7.54U/mg0.50621.24MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76192vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.eating behavior traitRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0002212food intake weight to change in body weight ratio4.7g/g0.20.5657MMO:0000160unspecified method0.0controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76197controlled in utero environment (for 9 days)vehicle control condition (for 30 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.eating behavior traitRS:0002943BluHsd:LEmale98 days to 71 days8CMO:0002209food calorie intake level to change in body weight ratio10.4kcal/g0.30.8485MMO:0000160unspecified method0.0controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76198controlled in utero environment (for 9 days)vehicle control condition (for 30 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.testis massRS:0002943BluHsd:LEmale98 days8CMO:0000175both testes wet weight3.4g0.30.8485MMO:0000005post excision weight measurement0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)76233vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney glutathione amountRS:0001014Hsd:WImale0 days6CMO:0002235kidney glutathione level12384.996ug/g257.1989630.006MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days)76238vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney glutathione amountRS:0001014Hsd:WImale0 days6CMO:0002235kidney glutathione level7882.758ug/g178.1573436.3944MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76239vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.testis massRS:0002943BluHsd:LEmale98 days8CMO:0000175both testes wet weight3.4g0.20.5657MMO:0000005post excision weight measurement0.0vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76249vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.blood testosterone amountRS:0002943BluHsd:LEmale98 days8CMO:0000568serum testosterone level7.3ng/ml1.54.2426MMO:0000073radioimmunoassay0.0tritium-basedvehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)76252vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.blood testosterone amountRS:0002943BluHsd:LEmale98 days8CMO:0000568serum testosterone level10ng/ml1.23.3941MMO:0000073radioimmunoassay0.0tritium-basedvehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76253vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.blood estradiol amountRS:0002943BluHsd:LEmale98 days8CMO:0000564serum estradiol level370pg/ml120.0339.4113MMO:0000073radioimmunoassay0.0tritium-basedvehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days)76254vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)
1543Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.blood estradiol amountRS:0002943BluHsd:LEmale98 days8CMO:0000564serum estradiol level290pg/ml10.028.2843MMO:0000073radioimmunoassay0.0tritium-basedvehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days)76255vehicle control condition (for 30 days)controlled in utero environment (for 9 days)maternal milk (for 21 days)controlled fat content diet (21.2 %) (for 28 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney lipid peroxide amountRS:0001014Hsd:WImale0 days6CMO:0002246kidney lipid peroxide level0.75nmol/mg0.01630.04MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days)76256vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney lipid peroxide amountRS:0001014Hsd:WImale0 days6CMO:0002246kidney lipid peroxide level1.51nmol/mg0.03270.08MMO:0000329liquid phase colorimetry0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 76257vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1558Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.blood estradiol amountRS:0000064Crl:CD(SD)female50 days32CMO:0000564serum estradiol level34.4pg/ml2.715.2735MMO:0000073radioimmunoassay0.0maternal milk (for 20 days) and vehicle control condition (for 15 days)76260maternal milk (for 20 days)vehicle control condition (for 15 days)
1558Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.blood progesterone amountRS:0000064Crl:CD(SD)female50 days32CMO:0000566serum progesterone level12.5ng/ml2.815.8392MMO:0000073radioimmunoassay0.0maternal milk (for 20 days) and vehicle control condition (for 15 days)76262maternal milk (for 20 days)vehicle control condition (for 15 days)
1558Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.mammary gland integrity traitRS:0000064Crl:CD(SD)female365 days to 0 days32CMO:0000343mammary tumor number2.840.311.7536MMO:0000158manual palpation method0.0maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)76264maternal milk (for 20 days)vehicle control condition (for 15 days)7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)
1558Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.mammary gland integrity traitRS:0000064Crl:CD(SD)female365 days to 0 days32CMO:0000345post-insult time to mammary tumor formationmedian65dMMO:0000158manual palpation method0.0maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)76267maternal milk (for 20 days)vehicle control condition (for 15 days)7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.body massRS:0001592HanTac:WHfemale0 days18CMO:0000420body weight gainG7-G2182.4g6.222526.4MMO:0000016body weighing method0.0vehicle control condition (for 14 days)76270vehicle control condition (for 14 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney massRS:0001014Hsd:WImale0 days6CMO:0000085both kidneys wet weight0.82g0.02450.06MMO:0000005post excision weight measurement0.0vehicle control condition (for 10 days)75956vehicle control condition (for 10 days)
1544Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.kidney massRS:0001014Hsd:WImale0 days6CMO:0000085both kidneys wet weight1.2g0.05310.13MMO:0000005post excision weight measurement0.0vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) 75957vehicle control condition (for 10 days)cisplatin (7.5 mg/kg)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.body massRS:0001592HanTac:WHmale1 days17CMO:0000012body weight6.2g0.12130.5MMO:0000016body weighing method0.0vehicle control condition (for 1 days)96612vehicle control condition (for 1 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.body massRS:0001592HanTac:WHfemale17 days to 16 days15CMO:0000012body weight29.1g0.67132.6MMO:0000016body weighing method0.0vehicle control condition (between 16 and 17 days)96687vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.stillborn offspring quantityRS:0001592HanTac:WHfemale0 days18CMO:0002383number of fetuses lost perinatally to litter size ratio8.5%1.88568.0MMO:0000163in vivo visual assessment0.0vehicle control condition (for 14 days)96592vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.total life spanRS:0001592HanTac:WHfemale0 days18CMO:0002384number of perinatal live-born offspring deaths to litter size ratio3.2%1.27285.4MMO:0000163in vivo visual assessment0.0vehicle control condition (for 14 days)96602vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.perineum lengthRS:0001592HanTac:WHmale1 days17CMO:0002385anogenital distance4.1mm0.0170.07MMO:0000417in vivo stereo light microscopy0.0vehicle control condition (for 1 days)96617vehicle control condition (for 1 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.testis massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000177right testis wet weight51.3mg1.79137.6MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96637vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.epididymis massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0001606both epididymides wet weight0.0228g9.0E-40.0038MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96652vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.seminal gland massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0001605both seminal vesicles wet weight7.1mg0.47142.0MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96657vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.skeletal muscle massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0002387combined levator ani and bulbocavernosus muscle weight26mg1.03714.4MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96662vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.liver massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000158liver wet weight0.7537g0.0270.1147MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96672vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.adrenal gland massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000164both adrenal glands wet weight7.5mg0.4952.1MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96677vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.ovary massRS:0001592HanTac:WHfemale17 days to 16 days15CMO:0002491left ovary wet weightleft ovary3.2mg0.26851.04MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96697vehicle control condition (between 16 and 17 days)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.arterial blood pressure traitRS:0000771WKY/Izmmale98 days6CMO:0000533absolute change in mean arterial blood pressure27mmHg3.07.3485MMO:0000011vascular indwelling catheter method0.0vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) 84566vehicle control condition (2 ul) (for 0 hours)air-jet exposure (for 0 hours)angiotensin II (20 ng)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.arterial blood pressure traitRS:0001054WKY.SHRSP-(D1Wox29-D1Arb21)/Izmmale98 days6CMO:0000533absolute change in mean arterial blood pressure32mmHg2.04.899MMO:0000011vascular indwelling catheter method0.0vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) 84568vehicle control condition (2 ul) (for 0 hours)air-jet exposure (for 0 hours)angiotensin II (20 ng)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.arterial blood pressure traitRS:0000771WKY/Izmmale98 days6CMO:0000533absolute change in mean arterial blood pressure50mmHg2.04.899MMO:0000011vascular indwelling catheter method0.0vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) 84570vehicle control condition (2 ul) (for 0 hours)air-jet exposure (for 0 hours)angiotensin II (20 ng) phenylephrine (3 ug)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.arterial blood pressure traitRS:0001054WKY.SHRSP-(D1Wox29-D1Arb21)/Izmmale98 days6CMO:0000533absolute change in mean arterial blood pressure50mmHg3.07.3485MMO:0000011vascular indwelling catheter method0.0vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) 84572vehicle control condition (2 ul) (for 0 hours)air-jet exposure (for 0 hours)angiotensin II (20 ng) phenylephrine (3 ug)
1601McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.blood alanine transaminase amountRS:0000363F344/NHsdnot specified84 days to 56 days4CMO:0000575serum alanine aminotransferase activity level35U/l11.022.0MMO:0000173spectrophotometry0.0fasting (between 12 and 15 hours) then vehicle control condition (for 1 days)84754fasting (between 12 and 15 hours)vehicle control condition (for 1 days)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.arterial blood pressure traitRS:0000771WKY/Izmmale98 days6CMO:0000533absolute change in mean arterial blood pressure-3mmHg2.04.899MMO:0000011vascular indwelling catheter method0.0air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours)84553air-jet exposure (for 0 hours)vehicle control condition (2 ul) (for 0 hours)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.arterial blood pressure traitRS:0001054WKY.SHRSP-(D1Wox29-D1Arb21)/Izmmale98 days6CMO:0000533absolute change in mean arterial blood pressure-1mmHg2.04.899MMO:0000011vascular indwelling catheter method0.0air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours)84555air-jet exposure (for 0 hours)vehicle control condition (2 ul) (for 0 hours)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.heart pumping traitRS:0000771WKY/Izmmale98 days6CMO:0000534absolute change in heart rate0beats/min6.014.6969MMO:0000011vascular indwelling catheter method0.0air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours)84562air-jet exposure (for 0 hours)vehicle control condition (2 ul) (for 0 hours)
1120Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.heart pumping traitRS:0001054WKY.SHRSP-(D1Wox29-D1Arb21)/Izmmale98 days6CMO:0000534absolute change in heart rate-5beats/min7.017.1464MMO:0000011vascular indwelling catheter method0.0air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours)84564air-jet exposure (for 0 hours)vehicle control condition (2 ul) (for 0 hours)
1601McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.blood alanine transaminase amountRS:0000698Hsd:SDnot specified84 days to 56 days4CMO:0000575serum alanine aminotransferase activity level30U/l1.02.0MMO:0000173spectrophotometry0.0fasting (between 12 and 15 hours) then vehicle control condition (for 1 days)84757fasting (between 12 and 15 hours)vehicle control condition (for 1 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.gestation period durationRS:0001592HanTac:WHfemale0 days18CMO:0000467gestation period length23d0.14140.6MMO:0000163in vivo visual assessment0.0vehicle control condition (for 14 days)96583vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.single birth offspring quantityRS:0001592HanTac:WHfemale0 days18CMO:0000642litter size11.80.77783.3MMO:0000163in vivo visual assessment0.0vehicle control condition (for 14 days)96597vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.single birth offspring quantityRS:0001592HanTac:WHfemale0 days18CMO:0002494number of male offspring to litter size ratio(number of males to litter size) ratio)50.5%4.360518.5MMO:0000163in vivo visual assessment0.0vehicle control condition (for 14 days)96607vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.perineum lengthRS:0001592HanTac:WHfemale1 days17CMO:0002385anogenital distance2.2mm0.02430.1MMO:0000417in vivo stereo light microscopy0.0vehicle control condition (for 1 days)96622vehicle control condition (for 1 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.nipple quantityRS:0001592HanTac:WHmale14 days17CMO:0002386areola mammae/nipple number0.10.04850.2MMO:0000163in vivo visual assessment0.0vehicle control condition (for 14 days)96627vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.body massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000012body weight28.6g1.08424.6MMO:0000016body weighing method0.0vehicle control condition (between 16 and 17 days)96632vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.testis massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000178left testis wet weight50.9mg1.74427.4MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96642vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.ventral prostate massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000850ventral prostate gland wet weight0.0117g8.0E-40.0036MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96647vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.ovary massRS:0001592HanTac:WHfemale17 days to 16 days15CMO:0002490right ovary wet weightright ovary2.9mg0.19880.77MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96692vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.thyroid gland massRS:0001592HanTac:WHfemale17 days to 16 days15CMO:0002392thyroid gland wet weightleft ovary4.7mg0.23240.9MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96707vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.retroperitoneal fat pad massRS:0001592HanTac:WHfemale17 days to 16 days15CMO:0000356retroperitoneal fat pad weight0.0295g0.00320.0123MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96712vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.embryonic growth traitRS:0001592HanTac:WHfemale0 days18CMO:0002382number of blastocysts/embryos lost postimplantation to litter size ratio7.9%2.710611.5MMO:0000160unspecified method0.0vehicle control condition (for 14 days)96588vehicle control condition (for 14 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.bulbourethral gland massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0002395bulbourethral gland wet weight1.7mg0.09430.4MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96667vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.retroperitoneal fat pad massRS:0001592HanTac:WHmale17 days to 16 days18CMO:0000356retroperitoneal fat pad weight0.038g0.00260.0112MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96682vehicle control condition (between 16 and 17 days)
1559Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.liver massRS:0001592HanTac:WHfemale17 days to 16 days15CMO:0000158liver wet weight0.7988g0.01720.0667MMO:0000005post excision weight measurement0.0vehicle control condition (between 16 and 17 days)96702vehicle control condition (between 16 and 17 days)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0000606left ventricular end-diastolic blood pressure13mmHg2.04.899MMO:0000014vascular transducer tipped catheter1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours)98826artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg) (for 0 hours)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0000606left ventricular end-diastolic blood pressure3mmHg1.02.4495MMO:0000014vascular transducer tipped catheter1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98827sham surgical control condition (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0000605left ventricular end-systolic blood pressure56mmHg3.07.3485MMO:0000014vascular transducer tipped catheter1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours)98838artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg) (for 0 hours)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0000605left ventricular end-systolic blood pressure64mmHg3.07.3485MMO:0000014vascular transducer tipped catheter1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98839sham surgical control condition (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricle massRS:0000681SDmale0 days6CMO:0000530heart left ventricle weight to body weight ratiog/g*1032.6mg/g0.10.2449MMO:0000005post excision weight measurement1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days)98874artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricle massRS:0000681SDmale0 days6CMO:0000530heart left ventricle weight to body weight ratiog/g*1032.3mg/g0.10.2449MMO:0000005post excision weight measurement1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days)98875sham surgical control condition (for 2 days)vehicle control condition (for 2 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.glomerular filtration traitRS:0000916WKY/NHsdmale0 days7CMO:0000765creatinine clearance3.1ml/min0.51.3229MMO:0000275urine creatinine analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99179standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.glomerular filtration traitRS:0000916WKY/NHsdmale0 days7CMO:0000765creatinine clearance3.5ml/min0.30.7937MMO:0000275urine creatinine analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99181controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0001745maximum rate of positive change in left ventricular blood pressure8259mmHg/s325.0796.0842MMO:0000014vascular transducer tipped catheter1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours)98886artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg) (for 0 hours)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0001745maximum rate of positive change in left ventricular blood pressure8231mmHg/s423.01036.1342MMO:0000014vascular transducer tipped catheter1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98887sham surgical control condition (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0001746maximum rate of negative change in left ventricular blood pressure-6032mmHg/s387.0947.9525MMO:0000014vascular transducer tipped catheter1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours)98890artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg) (for 0 hours)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart left ventricular blood pressure traitRS:0000681SDmale0 days6CMO:0001746maximum rate of negative change in left ventricular blood pressure-7197mmHg/s303.0742.1954MMO:0000014vascular transducer tipped catheter1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98891sham surgical control condition (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart pumping traitRS:0000681SDmale0 days6CMO:0000002heart rate420beats/min14.034.2929MMO:0000107HP Sonos 5500 echo ultrasound1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98801artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.heart pumping traitRS:0000681SDmale0 days6CMO:0000002heart rate380beats/min10.024.4949MMO:0000107HP Sonos 5500 echo ultrasound1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours)98802sham surgical control condition (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg) (for 0 hours)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.arterial blood pressure traitRS:0000681SDmale0 days6CMO:0000009mean arterial blood pressure72mmHg2.04.899MMO:0000014vascular transducer tipped catheter1.0ACF2daysartificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours)98814artificial aortocaval fistula (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg) (for 0 hours)
2160Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.arterial blood pressure traitRS:0000681SDmale0 days6CMO:0000009mean arterial blood pressure86mmHg4.09.798MMO:0000014vascular transducer tipped catheter1.0sham ACF2dayssham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) 98815sham surgical control condition (for 2 days)vehicle control condition (for 2 days)ketamine (80 mg/kg) (for 0 hours)xylazine (10 mg/kg)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.blood glucose amountRS:0000742WKYmale156 days10CMO:0000046blood glucose level160.56mg/dl8.6427.3221MMO:0000073radioimmunoassay0.0daysvehicle control condition (1 null) 99101vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.body massRS:0000742WKYmale156 days10CMO:0000012body weight450.39g9.3629.5989MMO:0000016body weighing method0.0daysvehicle control condition (1 null) 99107vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.kidney massRS:0000742WKYmale156 days10CMO:0000622single kidney wet weight to body weight ratio3.41g/kg0.341.0752MMO:0000005post excision weight measurement0.0daysvehicle control condition (1 null) 99113vehicle control condition (1 null)
2219Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.urine outputRS:0000742WKYmale156 days10CMO:0000260timed urine volume17.1ml/d1.574.9648MMO:0000357urine volume measurement method0.0daysvehicle control condition (1 null) 99119vehicle control condition (1 null)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days11CMO:0000046blood glucose level76mg/dl1.03.3166MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99970unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days17CMO:0000046blood glucose level324mg/dl13.053.6004MMO:0000190machine read blood glucose test strip0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99971unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days11CMO:0000037hematocrit45.2%1.44.6433MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99975unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days17CMO:0000037hematocrit44.8%0.62.4739MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99976unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days11CMO:0002783glomerular filtration rate to body weight ratio0.517ml/min/100g0.0110.0365MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99980unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days17CMO:0002783glomerular filtration rate to body weight ratio0.496ml/min/100g0.0290.1196MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99981unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days11CMO:0002943renal filtration fraction0.230.010.0332MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99985unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days17CMO:0002943renal filtration fraction0.2930.0110.0454MMO:0000634inulin analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99986unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days11CMO:0002782renal plasma flow to body weight ratio2.28ml/min/100g0.070.2322MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99990unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days17CMO:0002782renal plasma flow to body weight ratio1.72ml/min/100g0.110.4535MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99991unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.arterial blood pressure traitRS:0000742WKYmale0 days11CMO:0001898renal vascular resistance6.3mmHg/ml/min0.41.3266MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99995unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.arterial blood pressure traitRS:0000742WKYmale0 days17CMO:0001898renal vascular resistance16.7mmHg/ml/min1.45.7723MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99996unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days11CMO:0000260timed urine volume11.664ml/d1.0083.3432MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition100000unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days17CMO:0000260timed urine volume39.456ml/d4.60818.9993MMO:0000511metabolic cage urine volume measurement method0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition100001unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-diastolic diameterRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000982heart left ventricle end-diastolic diameter7.52mm0.320.8466MMO:0000337echocardiography0.0vehicle control condition99768vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-diastolic diameterRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000982heart left ventricle end-diastolic diameter8.68mm0.330.8731MMO:0000337echocardiography0.0vehicle control condition99770vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-diastolic diameterRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000982heart left ventricle end-diastolic diameter7.99mm0.621.6404MMO:0000337echocardiography0.0vehicle control condition99772vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle posterior wall thicknessRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0002597heart left ventricle end-diastolic posterior wall thickness2.03mm0.060.1587MMO:0000337echocardiography0.0vehicle control condition99774vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle posterior wall thicknessRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0001840heart left ventricle end-systolic posterior wall thickness3.29mm0.190.5027MMO:0000337echocardiography0.0vehicle control condition99792vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-diastolic diameterRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000985heart left ventricle fractional shortening47.3%4.110.8476MMO:0000337echocardiography0.0vehicle control condition99804vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000005diastolic blood pressureserial mean128mmHg22.058.2065MMO:0000031tail cuff plethysmography0.0vehicle control condition99822vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000005diastolic blood pressureserial mean142mmHg28.074.081MMO:0000031tail cuff plethysmography0.0vehicle control condition99824vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000005diastolic blood pressureserial mean145mmHg31.082.0183MMO:0000031tail cuff plethysmography0.0vehicle control condition99826vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000004systolic blood pressureserial mean172mmHg13.034.3948MMO:0000031tail cuff plethysmography0.0vehicle control condition99828vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000004systolic blood pressureserial mean195mmHg30.079.3725MMO:0000031tail cuff plethysmography0.0vehicle control condition99830vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000004systolic blood pressureserial mean197mmHg26.068.7895MMO:0000031tail cuff plethysmography0.0vehicle control condition99832vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000009mean arterial blood pressureserial mean142mmHg12.031.749MMO:0000031tail cuff plethysmography0.0vehicle control condition99834vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000009mean arterial blood pressureserial mean158mmHg27.071.4353MMO:0000031tail cuff plethysmography0.0vehicle control condition99836vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.arterial blood pressure traitRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000009mean arterial blood pressureserial mean162mmHg29.076.7268MMO:0000031tail cuff plethysmography0.0vehicle control condition99838vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.urine outputRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000260timed urine volume14.7ml/d2.66.879MMO:0000357urine volume measurement method0.0vehicle control condition99840vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.urine outputRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000260timed urine volume21.1ml/d7.620.1077MMO:0000357urine volume measurement method0.0vehicle control condition99842vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.urine outputRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000260timed urine volume19.5ml/d4.612.1705MMO:0000357urine volume measurement method0.0vehicle control condition99844vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days7CMO:0000012body weight268g13.034.3948MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99935unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days8CMO:0000012body weight215g10.028.2843MMO:0000016body weighing method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99936unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days7CMO:0000046blood glucose level74mg/dl2.05.2915MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99940unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.blood glucose amountRS:0000742WKYmale0 days8CMO:0000046blood glucose level350mg/dl18.050.9117MMO:0000190machine read blood glucose test strip0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99941unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days7CMO:0002783glomerular filtration rate to body weight ratio0.494ml/min/100g0.030.0794MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99945unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002783glomerular filtration rate to body weight ratio0.792ml/min/100g0.030.0849MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99946unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days7CMO:0002782renal plasma flow to body weight ratio2.16ml/min/100g0.180.4762MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99950unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney plasma flow traitRS:0000742WKYmale0 days8CMO:0002782renal plasma flow to body weight ratio3.09ml/min/100g0.180.5091MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99951unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days7CMO:0002943renal filtration fraction0.2330.0130.0344MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99955unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.glomerular filtration traitRS:0000742WKYmale0 days8CMO:0002943renal filtration fraction0.260.0130.0368MMO:0000634inulin analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99956unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.arterial blood pressure traitRS:0000742WKYmale0 days7CMO:0001898renal vascular resistance10mmHg/ml/min0.61.5875MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99960unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.arterial blood pressure traitRS:0000742WKYmale0 days8CMO:0001898renal vascular resistance9mmHg/ml/min0.41.1314MMO:0000636p-aminohippurate analysis by liquid phase colorimetry0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99961unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days7CMO:0000260timed urine volume12.384ml/d2.0165.3338MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then vehicle control condition99965unilateral nephrectomy (for 28 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.urine outputRS:0000742WKYmale0 days8CMO:0000260timed urine volume23.472ml/d1.7284.8875MMO:0000511metabolic cage urine volume measurement method0.0unx28daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99966unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle posterior wall thicknessRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0001840heart left ventricle end-systolic posterior wall thickness3.17mm0.170.4498MMO:0000337echocardiography0.0vehicle control condition99794vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle posterior wall thicknessRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0001840heart left ventricle end-systolic posterior wall thickness3.41mm0.51.3229MMO:0000337echocardiography0.0vehicle control condition99796vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.cardiac output traitRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000180ejection fraction83.3%4.311.3767MMO:0000337echocardiography0.0vehicle control condition99798vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.cardiac output traitRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000180ejection fraction80.2%3.48.9956MMO:0000337echocardiography0.0vehicle control condition99800vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.cardiac output traitRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000180ejection fraction77.4%6.015.8745MMO:0000337echocardiography0.0vehicle control condition99802vehicle control condition
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0002770skin chloride level to skin dry weight ratioskin cl mmol/g0.051mmol/g0.0030.0079MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skinstandard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99135standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0002770skin chloride level to skin dry weight ratioskin cl mmol/g0.068mmol/g0.0060.0159MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99137controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin water amountRS:0000916WKY/NHsdmale0 days7CMO:0002771skin water level to skin dry weight ratioskin h2o ml/g1.432ml/g0.0320.0847MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99141controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin mineral amountRS:0000916WKY/NHsdmale0 days7CMO:0002772skin potassium level plus skin sodium level to skin water level ratioskin na+k/h2o0.170.0010.0026MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skinstandard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99143standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin mineral amountRS:0000916WKY/NHsdmale0 days7CMO:0002772skin potassium level plus skin sodium level to skin water level ratioskin na+k/h2o0.1760.0080.0212MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99145controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0002775skin chloride level to skin water level ratioskin na/h2o90mmol/l0.82.1166MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skinstandard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99147standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0002775skin chloride level to skin water level ratioskin na/h2o101mmol/l3.910.3184MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99149controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0002775skin chloride level to skin water level ratioskin cl/h2o42mmol/l2.46.3498MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skinstandard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99151standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0002775skin chloride level to skin water level ratioskin cl/h2o48mmol/l4.812.6996MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99153controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin potassium amountRS:0000916WKY/NHsdmale0 days7CMO:0002773skin potassium level to skin water level ratioskin k/h2o80mmol/l1.12.9103MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skinstandard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99155standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin potassium amountRS:0000916WKY/NHsdmale0 days7CMO:0002773skin potassium level to skin water level ratioskin k/h2o71mmol/l3.07.9373MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99157controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood sodium amountRS:0000916WKY/NHsdmale0 days7CMO:0000060plasma sodium level143.7mmol/l4.411.6413MMO:0000037automated blood electrolyte analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99159standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood sodium amountRS:0000916WKY/NHsdmale0 days7CMO:0000060plasma sodium level141.4mmol/l2.15.5561MMO:0000037automated blood electrolyte analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99161controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood potassium amountRS:0000916WKY/NHsdmale0 days7CMO:0000061plasma potassium level3.9mmol/l0.20.5292MMO:0000037automated blood electrolyte analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99163standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood potassium amountRS:0000916WKY/NHsdmale0 days7CMO:0000061plasma potassium level4.2mmol/l0.30.7937MMO:0000037automated blood electrolyte analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99165controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0000059plasma chloride level98.2mmol/l1.12.9103MMO:0000037automated blood electrolyte analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99167standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood creatinine amountRS:0000916WKY/NHsdmale0 days7CMO:0000537plasma creatinine level0.30882306mg/dl0.01020.0269MMO:0000306plasma creatinine analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99171standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood creatinine amountRS:0000916WKY/NHsdmale0 days7CMO:0000537plasma creatinine level0.30090452mg/dl0.00790.021MMO:0000306plasma creatinine analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99173controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood cystatin C amountRS:0000916WKY/NHsdmale0 days7CMO:0002778plasma cystatin C level4mg/l0.61.5875MMO:0000352automated plasma protein analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99175standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood cystatin C amountRS:0000916WKY/NHsdmale0 days7CMO:0002778plasma cystatin C level3.5mg/l0.20.5292MMO:0000352automated plasma protein analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99177controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-diastolic diameterRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000985heart left ventricle fractional shortening44.3%2.87.4081MMO:0000337echocardiography0.0vehicle control condition99806vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-diastolic diameterRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000985heart left ventricle fractional shortening41.6%5.614.8162MMO:0000337echocardiography0.0vehicle control condition99808vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle massRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000776heart left ventricle weight1.53g0.080.2117MMO:0000337echocardiography0.0vehicle control condition99810vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle massRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000776heart left ventricle weight1.67g0.060.1587MMO:0000337echocardiography0.0vehicle control condition99812vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle massRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000776heart left ventricle weight1.78g0.040.1058MMO:0000337echocardiography0.0vehicle control condition99814vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart pumping traitRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000002heart rate382beats/min45.0119.0588MMO:0000337echocardiography0.0vehicle control condition99816vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart pumping traitRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000002heart rate349beats/min20.052.915MMO:0000337echocardiography0.0vehicle control condition99818vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart pumping traitRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000002heart rate327beats/min19.050.2693MMO:0000337echocardiography0.0vehicle control condition99820vehicle control condition
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin sodium amountRS:0000916WKY/NHsdmale0 days7CMO:0002769skin sodium level to skin dry weight ratiommol/g0.11REQUEST NEW VALUE0.0030.0079MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skinstandard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99131standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.skin sodium amountRS:0000916WKY/NHsdmale0 days7CMO:0002769skin sodium level to skin dry weight ratiommol/g0.144REQUEST NEW VALUE0.0050.0132MMO:0000584ex vivo analysis of atomic composition following dry ashing0.0ashed skincontrolled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99133controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.blood chloride amountRS:0000916WKY/NHsdmale0 days7CMO:0000059plasma chloride level104.8mmol/l1.84.7624MMO:0000037automated blood electrolyte analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99169controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.urine sodium amountRS:0000916WKY/NHsdmale0 days7CMO:0000760urine sodium excretion ratemmol/d1mEq/d0.20.5292MMO:0000434urine sodium analysis0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99183standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.urine sodium amountRS:0000916WKY/NHsdmale0 days7CMO:0000760urine sodium excretion rate41.9mEq/d5.213.7579MMO:0000434urine sodium analysis0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99185controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.arterial blood pressure traitRS:0000916WKY/NHsdmale0 days7CMO:0000009mean arterial blood pressure101mmHg0.92.3812MMO:0000577intra-aortic radiotelemetry0.0standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99187standard rat chow (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
2238Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.arterial blood pressure traitRS:0000916WKY/NHsdmale0 days7CMO:0000009mean arterial blood pressure116mmHg1.02.6458MMO:0000577intra-aortic radiotelemetry0.0controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days)99189controlled sodium content diet (8 %) (for 8 days)0.9% sodium chloride solution (0.9 %) (for 8 days)vehicle control condition (0.5 ml) (for 8 days)
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricular blood pressure traitRS:0000811SS/JrHsdMcwimale56 days6CMO:0003281right ventricular end-systolic blood pressure26mmHg0.992.425MMO:0000013vascular fluid filled catheter0.0vehicle control condition106796vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricular blood pressure traitRS:0001480SS-Sod3m1Mcwimale56 days15CMO:0003281right ventricular end-systolic blood pressure25.1mmHg0.532.0527MMO:0000013vascular fluid filled catheter0.0vehicle control condition106797vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.body massRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000012body weight425g22.058.2065MMO:0000016body weighing method0.0vehicle control condition99758vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.body massRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000012body weight452g21.055.5608MMO:0000016body weighing method0.0vehicle control condition99760vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart ventricle septum thicknessRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0002791heart interventricular end-diastolic septal wall thickness2.01mm0.080.2117MMO:0000337echocardiography0.0vehicle control condition99762vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart ventricle septum thicknessRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0002791heart interventricular end-diastolic septal wall thickness1.92mm0.120.3175MMO:0000337echocardiography0.0vehicle control condition99764vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart ventricle septum thicknessRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0002791heart interventricular end-diastolic septal wall thickness2.26mm0.230.6085MMO:0000337echocardiography0.0vehicle control condition99766vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle posterior wall thicknessRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0002597heart left ventricle end-diastolic posterior wall thickness1.89mm0.160.4233MMO:0000337echocardiography0.0vehicle control condition99776vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle posterior wall thicknessRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0002597heart left ventricle end-diastolic posterior wall thickness2.17mm1.945.1328MMO:0000337echocardiography0.0vehicle control condition99778vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart ventricle septum thicknessRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0002792heart interventricular end-systolic septal wall thickness3.19mm0.20.5292MMO:0000337echocardiography0.0vehicle control condition99780vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart ventricle septum thicknessRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0002792heart interventricular end-systolic septal wall thickness3.24mm0.210.5556MMO:0000337echocardiography0.0vehicle control condition99782vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart ventricle septum thicknessRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0002792heart interventricular end-systolic septal wall thickness3.48mm0.260.6879MMO:0000337echocardiography0.0vehicle control condition99784vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-systolic diameterRS:0003075SS-Nppbem2Mcwi-/-male84 days7CMO:0000983heart left ventricle end-systolic diameter3.98mm0.451.1906MMO:0000337echocardiography0.0vehicle control condition99786vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-systolic diameterRS:0003075SS-Nppbem2Mcwi-/-male168 days7CMO:0000983heart left ventricle end-systolic diameter4.83mm0.350.926MMO:0000337echocardiography0.0vehicle control condition99788vehicle control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.heart left ventricle end-systolic diameterRS:0003075SS-Nppbem2Mcwi-/-male252 days7CMO:0000983heart left ventricle end-systolic diameter4.67mm0.741.9579MMO:0000337echocardiography0.0vehicle control condition99790vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.body massRS:0000592MWmale0 days7CMO:0000012body weight220g9.023.8118MMO:0000119body measuring method0.0unx14daysunilateral nephrectomy (for 14 days) then vehicle control condition101142unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.body massRS:0000592MWmale0 days7CMO:0000012body weight260g6.015.8745MMO:0000119body measuring method0.0unx42daysunilateral nephrectomy (for 14 days) then vehicle control condition101146unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.body massRS:0000592MWmale0 days7CMO:0000012body weight286g9.023.8118MMO:0000119body measuring method0.0unx70daysunilateral nephrectomy (for 70 days) then vehicle control condition101154unilateral nephrectomy (for 70 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.arterial blood pressure traitRS:0000592MWmale0 days7CMO:0000004systolic blood pressureundefined118mmHg2.05.2915MMO:0000031tail cuff plethysmography0.0unx14daysunilateral nephrectomy (for 14 days) then vehicle control condition101159unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.arterial blood pressure traitRS:0000592MWmale0 days7CMO:0000004systolic blood pressureundefined118mmHg2.05.2915MMO:0000031tail cuff plethysmography0.0unx42daysunilateral nephrectomy (for 14 days) then vehicle control condition101163unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.arterial blood pressure traitRS:0000592MWmale0 days7CMO:0000004systolic blood pressureundefined122mmHg2.05.2915MMO:0000031tail cuff plethysmography0.0unx70daysunilateral nephrectomy (for 70 days) then vehicle control condition101168unilateral nephrectomy (for 70 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.arterial blood pressure traitRS:0000592MWmale0 days7CMO:0000009mean arterial blood pressureundefined108mmHg2.05.2915MMO:0000011vascular indwelling catheter method0.0unx70daysunilateral nephrectomy (for 70 days) then vehicle control condition101173unilateral nephrectomy (for 70 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.blood urea nitrogen amountRS:0000592MWmale0 days7CMO:0000049blood urea nitrogen level25mg/dl1.02.6458MMO:0000253blood urea nitrogen analysis0.0unx14daysunilateral nephrectomy (for 14 days) then vehicle control condition101178unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.blood urea nitrogen amountRS:0000592MWmale0 days7CMO:0000049blood urea nitrogen level25mg/dl3.07.9373MMO:0000253blood urea nitrogen analysis0.0unx42daysunilateral nephrectomy (for 14 days) then vehicle control condition101182unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.blood urea nitrogen amountRS:0000592MWmale0 days7CMO:0000049blood urea nitrogen level26mg/dl1.02.6458MMO:0000253blood urea nitrogen analysis0.0unx70daysunilateral nephrectomy (for 70 days) then vehicle control condition101187unilateral nephrectomy (for 70 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.total urine protein amountRS:0000592MWmale0 days7CMO:0000756urine total protein excretion rate11mg/d2.05.2915MMO:0000426Bradford protein assay0.0unx14daysunilateral nephrectomy (for 14 days) then vehicle control condition101192unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.total urine protein amountRS:0000592MWmale0 days7CMO:0000756urine total protein excretion rate23mg/d2.05.2915MMO:0000426Bradford protein assay0.0unx42daysunilateral nephrectomy (for 14 days) then vehicle control condition101196unilateral nephrectomy (for 14 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.total urine protein amountRS:0000592MWmale0 days7CMO:0000756urine total protein excretion rate18mg/d4.010.583MMO:0000426Bradford protein assay0.0unx70daysunilateral nephrectomy (for 70 days) then vehicle control condition101200unilateral nephrectomy (for 70 days)vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.total urine protein amountRS:0000592MWmale0 days18CMO:0000756urine total protein excretion rate8mg/d2.08.4853MMO:0000426Bradford protein assay0.0control29daysvehicle control condition101203vehicle control condition
2581Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.glomerular filtration traitRS:0000592MWmale0 days7CMO:0000490glomerular filtration rate1.46ml/min0.080.2117MMO:0000634inulin analysis by liquid phase colorimetry0.0unx70daysunilateral nephrectomy (for 70 days) then vehicle control condition101205unilateral nephrectomy (for 70 days)vehicle control condition
2583Kohara K, et al., Hypertension. 1993 Jun;21(6 Pt 2):975-9.blood sodium amountRS:0000752SHR/NCrlCrljmale126 days5CMO:0000499blood sodium level140mmol/l1.02.2361MMO:0000142automated serum sodium test0.0unx42daysunilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days)101238unilateral nephrectomy (for 42 days)vehicle control condition (for 28 days)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days6CMO:0000009mean arterial blood pressureundefined138mmHg9.022.0454MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103015air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days7CMO:0000009mean arterial blood pressureundefined128mmHg9.023.8118MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103016air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days5CMO:0000009mean arterial blood pressureundefined137mmHg6.013.4164MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103017air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days7CMO:0000009mean arterial blood pressureundefined147mmHg7.018.5203MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103018air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days6CMO:0000009mean arterial blood pressureundefined90mmHg8.019.5959MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103019air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days7CMO:0000009mean arterial blood pressureundefined96mmHg8.021.166MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103020air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days5CMO:0000009mean arterial blood pressureundefined108mmHg8.017.8885MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103021air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days7CMO:0000009mean arterial blood pressureundefined111mmHg5.013.2288MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103022air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days6CMO:0000009mean arterial blood pressureundefined99mmHg7.017.1464MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103023air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days7CMO:0000009mean arterial blood pressureundefined109mmHg10.026.4575MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103024air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days7CMO:0000009mean arterial blood pressureundefined123mmHg5.013.2288MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103026air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days6CMO:0000009mean arterial blood pressureundefined155mmHg10.024.4949MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours)103027air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days7CMO:0000009mean arterial blood pressureundefined136mmHg13.034.3948MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours)103028air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days5CMO:0000009mean arterial blood pressureundefined151mmHg1.02.2361MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours)103029air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days7CMO:0000009mean arterial blood pressureundefined140mmHg8.021.166MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours)103030air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days6CMO:0000009mean arterial blood pressureundefined120mmHg7.017.1464MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103031air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001840Crlj:WImale16 days7CMO:0000009mean arterial blood pressureundefined102mmHg11.029.1033MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103032air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days5CMO:0000009mean arterial blood pressureundefined137mmHg3.06.7082MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103033air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days7CMO:0000009mean arterial blood pressureundefined143mmHg3.07.9373MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103034air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days6CMO:0000002heart rate372beats/min11.026.9444MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103035air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days7CMO:0000002heart rate415beats/min10.026.4575MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103036air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days5CMO:0000002heart rate395beats/min17.038.0132MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103037air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days7CMO:0000002heart rate147beats/min7.018.5203MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours)103038air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days6CMO:0000002heart rate90beats/min15.036.7423MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103039air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days7CMO:0000002heart rate380beats/min18.047.6235MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103040air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days5CMO:0000002heart rate366beats/min17.038.0132MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103041air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days7CMO:0000002heart rate379beats/min9.023.8118MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103042air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days6CMO:0000002heart rate351beats/min19.046.5403MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103043air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days7CMO:0000002heart rate384beats/min17.044.9778MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103044air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days5CMO:0000002heart rate366beats/min17.038.0132MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103045air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days7CMO:0000002heart rate390beats/min10.026.4575MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103046air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days6CMO:0000002heart rate288beats/min11.026.9444MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours)103047air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days7CMO:0000002heart rate287beats/min7.018.5203MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours)103048air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days5CMO:0000002heart rate301beats/min21.046.9574MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours)103049air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days7CMO:0000002heart rate344beats/min11.029.1033MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours)103050air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days6CMO:0000002heart rate275beats/min8.019.5959MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103051air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001840Crlj:WImale16 days7CMO:0000002heart rate264beats/min9.023.8118MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103052air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days5CMO:0000002heart rate252beats/min25.055.9017MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103053air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.heart pumping traitRS:0001299GKmale16 days7CMO:0000002heart rate279beats/min17.044.9778MMO:0000014vascular transducer tipped catheter0.0air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours)103054air oxygen content (5 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours)meclofenamate (3 mg/kg) (for 0.5 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.heart pumping traitRS:0001299GKmale168 days6CMO:0000002heart ratenighttime measurement323beats/min8.019.5959MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours)103568vehicle control condition (for 28 days)dark phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.voluntary movement traitRS:0000731WKY/NCrlmale168 days6CMO:0003644number of spontaneous locomotor movements per unit timenumber of spontaneous locomotor movements per unit time (CMO:0003644)0.9/min0.10.2449MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours)103574vehicle control condition (between 1 and 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.voluntary movement traitRS:0001299GKmale168 days6CMO:0003644number of spontaneous locomotor movements per unit timenumber of spontaneous locomotor movements per unit time (CMO:0003644)0.9/min0.10.2449MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours)103576vehicle control condition (between 1 and 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.voluntary movement traitRS:0000731WKY/NCrlmale168 days6CMO:0003644number of spontaneous locomotor movements per unit timenumber of spontaneous locomotor movements per unit time (CMO:0003644)2.8/min0.30.7348MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle103582vehicle control condition (between 1 and 28 days)dark phase of controlled light/dark cycle
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.voluntary movement traitRS:0001299GKmale168 days6CMO:0003644number of spontaneous locomotor movements per unit timenumber of spontaneous locomotor movements per unit time (CMO:0003644)2.9/min0.10.2449MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle103584vehicle control condition (between 1 and 28 days)dark phase of controlled light/dark cycle
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000725logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-7.070.0540.1429MMO:0000342wire myographyvehicle control condition (for 28 days)103586vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000725logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-7.290.0920.2602MMO:0000342wire myography0.0vehicle control condition (for 28 days)103588vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000731acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel89.88%2.566.7731MMO:0000342wire myography0.0vehicle control condition (for 28 days)103590vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000731acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel67.1%3.329.3904MMO:0000342wire myography0.0vehicle control condition (for 28 days)103592vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000727logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-8.0580.0480.127MMO:0000342wire myography0.0vehicle control condition (for 28 days)103594vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000727logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-7.960.0480.1358MMO:0000342wire myography0.0vehicle control condition (for 28 days)103596vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000732sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel97.56%1.022.6987MMO:0000342wire myography0.0vehicle control condition (for 28 days)103598vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000732sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel94.07%1.1253.182MMO:0000342wire myography0.0vehicle control condition (for 28 days)103600vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000725logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-7.60.050.1323MMO:0000342wire myography0.0vehicle control condition (for 28 days)103602vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000725logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-7.390.040.1131MMO:0000342wire myography0.0vehicle control condition (for 28 days)103604vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000731acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel99.75%2.326.1381MMO:0000342wire myography0.0vehicle control condition (for 28 days)103606vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000731acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel96.96%2.26.2225MMO:0000342wire myography0.0vehicle control condition (for 28 days)103608vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000727logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-8.150.0890.2355MMO:0000342wire myography0.0vehicle control condition (for 28 days)103610vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000727logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)-8.740.571.6122MMO:0000342wire myography0.0vehicle control condition (for 28 days)103612vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0000731WKY/NCrlmale168 days7CMO:0000732sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel96.54%1.95.0269MMO:0000342wire myography0.0vehicle control condition (for 28 days)103614vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.vasodilation traitRS:0001299GKmale168 days8CMO:0000732sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel86.87%3.068.655MMO:0000342wire myography0.0vehicle control condition (for 28 days)103616vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.artery molecular composition traitRS:0000731WKY/NCrlmale175 days7CMO:0002853aorta wall phosphorylated eNOS level to total eNOS level ratio1.450.210.5556MMO:0000669western blot assay0.0vehicle control condition (for 35 days)103618vehicle control condition (for 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.artery molecular composition traitRS:0001299GKmale175 days8CMO:0002853aorta wall phosphorylated eNOS level to total eNOS level ratio1.610.30.8485MMO:0000669western blot assay0.0vehicle control condition (for 35 days)103620vehicle control condition (for 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.artery molecular composition traitRS:0000731WKY/NCrlmale175 days7CMO:0002852mesenteric artery phosphorylated eNOS level to total eNOS level ratio0.940.130.3439MMO:0000669western blot assay0.0vehicle control condition (for 35 days)103622vehicle control condition (for 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.artery molecular composition traitRS:0001299GKmale175 days8CMO:0002852mesenteric artery phosphorylated eNOS level to total eNOS level ratio0.90.070.198MMO:0000669western blot assay0.0vehicle control condition (for 35 days)103624vehicle control condition (for 35 days)
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood glucose amountRS:0001366LL/Mavmale56 days to 49 days13CMO:0000046blood glucose level65mg/dl1.03.6056MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours)102656vehicle control conditionfasting (for 16 hours)
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood glucose amountRS:0000556LH/Mavmale56 days to 49 days8CMO:0000046blood glucose level67mg/dl1.02.8284MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours)102657vehicle control conditionfasting (for 16 hours)
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood glucose amountRS:0001366LL/Mavmale56 days to 49 days13CMO:0000046blood glucose level132mg/dl4.014.4222MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours)102659vehicle control conditionfasting (for 16 hours)glucose (2 g/kg) (for 1 hours)
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood glucose amountRS:0000556LH/Mavmale56 days to 49 days8CMO:0000046blood glucose level121mg/dl6.016.9706MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours)102660vehicle control conditionfasting (for 16 hours)glucose (2 g/kg) (for 1 hours)
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood cholesterol amountRS:0001366LL/Mavmale112 days13CMO:0000585plasma total cholesterol level50.5791mg/dl2.70279.7447MMO:0000491blood cholesterol analysis0.0vehicle control condition102662vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood cholesterol amountRS:0000556LH/Mavmale112 days8CMO:0000585plasma total cholesterol level66.4092mg/dl5.405415.2888MMO:0000491blood cholesterol analysis0.0vehicle control condition102663vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood triglyceride amountRS:0001366LL/Mavmale112 days13CMO:0000548plasma triglyceride level1.58mmol/l0.130.4687MMO:0000234plasma triglyceride analysis0.0vehicle control condition102668vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood triglyceride amountRS:0000556LH/Mavmale112 days8CMO:0000548plasma triglyceride level1.57mmol/l0.060.1697MMO:0000234plasma triglyceride analysis0.0vehicle control condition102669vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood creatinine amountRS:0001366LL/Mavmale112 days13CMO:0000537plasma creatinine level0.518mg/dl0.010.0361MMO:0000306plasma creatinine analysis0.0vehicle control condition102674vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.blood creatinine amountRS:0000554LH/MavRrrcmale112 days8CMO:0000537plasma creatinine level0.53mg/dl0.0120.0339MMO:0000306plasma creatinine analysis0.0vehicle control condition102675vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.heart left ventricle massRS:0001366LL/Mavmale112 days13CMO:0000530heart left ventricle weight to body weight ratio20.4mg/g0.10.3606MMO:0000005post excision weight measurement0.0vehicle control condition102680vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.heart left ventricle massRS:0000554LH/MavRrrcmale112 days8CMO:0000530heart left ventricle weight to body weight ratio23mg/g0.20.5657MMO:0000005post excision weight measurement0.0vehicle control condition102681vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.aorta massRS:0001366LL/Mavmale112 days13CMO:0003216aorta weight to body weight ratio11.6mg/100g0.31.0817MMO:0000005post excision weight measurement0.0vehicle control condition102686vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.aorta massRS:0000554LH/MavRrrcmale112 days8CMO:0003216aorta weight to body weight ratio12.2mg/100g0.20.5657MMO:0000005post excision weight measurement0.0vehicle control condition102687vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.kidney massRS:0001366LL/Mavmale112 days13CMO:0000340both kidneys wet weight to body weight ratio6.53g/kg0.040.1442MMO:0000005post excision weight measurement0.0vehicle control condition102692vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.kidney massRS:0000554LH/MavRrrcmale112 days8CMO:0000340both kidneys wet weight to body weight ratio6.36g/kg0.080.2263MMO:0000005post excision weight measurement0.0vehicle control condition102693vehicle control condition
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.arterial blood pressure traitRS:0004500SD-Nfe2l2em1Mcwi+/+male11 days to 9 days4CMO:0000009mean arterial blood pressure95mmHg3.97.8MMO:0000013vascular fluid filled catheter0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days)100739controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.arterial blood pressure traitRS:0004501SD-Nfe2l2em1Mcwi-/-male11 days to 9 days3CMO:0000009mean arterial blood pressure102mmHg3.05.1962MMO:0000013vascular fluid filled catheter0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days)100740controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.cerebral artery size traitRS:0004500SD-Nfe2l2em1Mcwi+/+male11 days to 9 days5CMO:0001128middle cerebral artery inner diametermax dilation246um4.810.7331MMO:0000027ex vivo method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) 100745controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)controlled calcium ion content physiological salt solution perfusate (0 %)
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.cerebral artery size traitRS:0004501SD-Nfe2l2em1Mcwi-/-male11 days to 9 days4CMO:0001128middle cerebral artery inner diametermax dilation248um9.018.0MMO:0000027ex vivo method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) 100746controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)controlled calcium ion content physiological salt solution perfusate (0 %)
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.cerebral artery size traitRS:0004500SD-Nfe2l2em1Mcwi+/+male11 days to 9 days5CMO:0001128middle cerebral artery inner diameterresting diameter145um12.527.9508MMO:0000027ex vivo method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate100751controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)physiological salt solution perfusate
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.cerebral artery size traitRS:0004501SD-Nfe2l2em1Mcwi-/-male11 days to 9 days4CMO:0001128middle cerebral artery inner diameterresting diameter154um15.030.0MMO:0000027ex vivo method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate100752controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)physiological salt solution perfusate
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.cerebral artery size traitRS:0004500SD-Nfe2l2em1Mcwi+/+male11 days to 9 days5CMO:0001190percent change in middle cerebral artery inner diametertone41.4%4.479.9952MMO:0000027ex vivo method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate100757controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)physiological salt solution perfusate
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.cerebral artery size traitRS:0004501SD-Nfe2l2em1Mcwi-/-male11 days to 9 days4CMO:0001190percent change in middle cerebral artery inner diametertone37.4%6.5313.06MMO:0000027ex vivo method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate100758controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)physiological salt solution perfusate
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood cholesterol amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000363serum total cholesterol level333mg/dl15.638.212MMO:0000132serum total cholesterol measurement test0.0vehicle control condition (0.5 %) (for 28 days)101941vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood LDL cholesterol amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000362serum low density lipoprotein cholesterol level102.5mg/dl9.3722.9517MMO:0000134serum low-density lipoprotein-cholesterol measurement test0.0vehicle control condition (0.5 %) (for 28 days)101944vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood HDL cholesterol amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000361serum high density lipoprotein cholesterol level97.25mg/dl15.3337.5507MMO:0000133serum high-density lipoprotein-cholesterol measurement test0.0vehicle control condition (0.5 %) (for 28 days)101947vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood triglyceride amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000360serum triglyceride level2196.13mg/dl204.52500.9696MMO:0000136serum triglyceride analysis0.0vehicle control condition (0.5 %) (for 28 days)101950vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood free fatty acid amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000547serum free fatty acids level1.42mmol/l0.140.3429MMO:0000308serum free fatty acid analysis0.0vehicle control condition (0.5 %) (for 28 days)101953vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood glucose amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000543serum glucose level149.4mg/dl12.3630.2757MMO:0000316serum glucose analysis0.0vehicle control condition (0.5 %) (for 28 days)101956vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood insulin amountRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days6CMO:0000358serum insulin level0.000807mg/dl1.0E-42.0E-4MMO:0000322serum insulin analysis0.0vehicle control condition (0.5 %) (for 28 days)101959vehicle control condition (0.5 %) (for 28 days)
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.body massRS:0001366LL/Mavmale56 days to 49 days13CMO:0000012body weight219g5.018.0278MMO:0000016body weighing method0.0vehicle control condition102641vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.body massRS:0000556LH/Mavmale56 days to 49 days8CMO:0000012body weight232g6.016.9706MMO:0000016body weighing method0.0vehicle control condition102642vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.arterial blood pressure traitRS:0001366LL/Mavmale56 days to 49 days13CMO:0000004systolic blood pressureundefined115mmHg3.010.8167MMO:0000031tail cuff plethysmography0.0vehicle control condition102644vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.arterial blood pressure traitRS:0000556LH/Mavmale56 days to 49 days8CMO:0000004systolic blood pressureundefined136mmHg3.08.4853MMO:0000031tail cuff plethysmography0.0vehicle control condition102645vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.urine outputRS:0001366LL/Mavmale56 days to 49 days13CMO:0000260timed urine volume8.4ml/d0.31.0817MMO:0000357urine volume measurement method0.0vehicle control condition102647vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.urine outputRS:0000556LH/Mavmale56 days to 49 days8CMO:0000260timed urine volume8.7ml/d0.61.6971MMO:0000357urine volume measurement method0.0vehicle control condition102648vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.urine creatinine amountRS:0001366LL/Mavmale56 days to 49 days13CMO:0000764urine creatinine excretion rate7.1mg/d0.31.0817MMO:0000275urine creatinine analysis0.0vehicle control condition102650vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.urine creatinine amountRS:0000556LH/Mavmale56 days to 49 days8CMO:0000764urine creatinine excretion rate8mg/d0.30.8485MMO:0000275urine creatinine analysis0.0vehicle control condition102651vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.total urine protein amountRS:0001366LL/Mavmale56 days to 49 days13CMO:0002758urine protein level to urine creatinine level ratio2.70.10.3606MMO:0000334urine protein analysis0.0vehicle control condition102653vehicle control condition
2703Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.total urine protein amountRS:0000556LH/Mavmale56 days to 49 days8CMO:0002758urine protein level to urine creatinine level ratio5.90.51.4142MMO:0000334urine protein analysis0.0vehicle control condition102654vehicle control condition
2541Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.body massRS:0003240MWF/ZtmRrrcmale126 days8CMO:0000012body weight378g10.606630.0MMO:0000016body weighing method0.0vehicle control condition100901vehicle control condition
2541Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.body massRS:0003240MWF/ZtmRrrcmale126 days7CMO:0000012body weight385g11.338930.0MMO:0000016body weighing method0.0vehicle control condition100903vehicle control condition
2541Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.body massRS:0003240MWF/ZtmRrrcmale246 days8CMO:0000012body weight433g9.192426.0MMO:0000016body weighing method0.0vehicle control condition100905vehicle control condition
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.tibia lengthRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0001731tibia straight segment length34.62mm0.150.5408MMO:0000119body measuring method0.0vehicle control condition (0.5 %) (for 28 days)101971vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart massRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0001198heart weight to tibia length ratio0.4295g/cm0.01150.0415MMO:0000005post excision weight measurement0.0vehicle control condition (0.5 %) (for 28 days)101974vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricle massRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0002787heart left ventricle weight to tibia length ratiolv/tl0.3101g/cm0.0090.0324MMO:0000005post excision weight measurement0.0vehicle control condition (0.5 %) (for 28 days)101977vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.retroperitoneal fat pad massRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0002990retroperitoneal fat pad weight to tibia length ratiorf/tl429.56mg/mm13.6449.1797MMO:0000005post excision weight measurement0.0vehicle control condition (0.5 %) (for 28 days)101980vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.epididymal fat pad massRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0001201epididymal fat pad weight to tibia length ratioef/tl3.5481g/cm0.09750.3515MMO:0000005post excision weight measurement0.0vehicle control condition (0.5 %) (for 28 days)101983vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.mesenteric fat pad massRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0003286mesenteric fat pad weight to tibia length ratiomf/tl364.22mg/mm10.3337.2453MMO:0000005post excision weight measurement0.0vehicle control condition (0.5 %) (for 28 days)101986vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.inguinal fat pad massRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0002991inguinal fat pad weight to tibia length ratioif/tl1501.32mg/mm68.53247.0884MMO:0000005post excision weight measurement0.0vehicle control condition (0.5 %) (for 28 days)101989vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricle wall thicknessRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000987heart ventricle septal wall thickness0.206cm0.0030.0108MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)101992vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricle end-diastolic diameterRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000982heart left ventricle end-diastolic diameter8.27mm0.130.4687MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)101995vehicle control condition (0.5 %) (for 28 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.body massRS:0003328SS/NEisSlcmale126 days8CMO:0000012body weight361g9.025.4558MMO:0000016body weighing method0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102311controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.arterial blood pressure traitRS:0003328SS/NEisSlcmale126 days8CMO:0000004systolic blood pressureundefined226mmHg11.031.1127MMO:0000031tail cuff plethysmography0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102314controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.heart left ventricle end-diastolic diameterRS:0003328SS/NEisSlcmale126 days8CMO:0000985heart left ventricle fractional shortening24.8%1.23.3941MMO:0000002transthoracic echocardiography0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102317controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0000731WKY/NCrlmale168 days6CMO:0000004systolic blood pressuredaytime measurement121mmHg3.07.3485MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours)103526vehicle control condition (for 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0001299GKmale168 days6CMO:0000004systolic blood pressuredaytime measurement145mmHg4.09.798MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours)103528vehicle control condition (for 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0000731WKY/NCrlmale168 days6CMO:0000004systolic blood pressurenighttime measurement126mmHg3.07.3485MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours)103534vehicle control condition (for 28 days)dark phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0001299GKmale168 days6CMO:0000004systolic blood pressurenighttime measurement145mmHg4.09.798MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours)103536vehicle control condition (for 28 days)dark phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0000731WKY/NCrlmale168 days6CMO:0000005diastolic blood pressuredaytime measurement85mmHg3.07.3485MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours)103542vehicle control condition (for 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0001299GKmale168 days6CMO:0000005diastolic blood pressuredaytime measurement98mmHg2.04.899MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours)103544vehicle control condition (for 28 days)light phase of controlled light/dark cycle (for 12 hours)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0001013WImale547 days4CMO:0002832neuron mitochondrion area to neuron cytoplasm area ratiomito/cyto10.4%0.160.32MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103644vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0000634OXYS/Novmale547 days4CMO:0002832neuron mitochondrion area to neuron cytoplasm area ratiomito/cyto3.6%0.10.2MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103645vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0001013WImale547 days4CMO:0002836neuron lysosome area to neuron cytoplasm area ratiolys/cyto8.3%0.190.38MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103647vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0000634OXYS/Novmale547 days4CMO:0002836neuron lysosome area to neuron cytoplasm area ratiolys/cyto11.9%0.390.78MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103648vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0001013WImale547 days4CMO:0002840neuron golgi apparatus area to neuron cytoplasm area ratioga/cyto1.05%0.040.08MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103650vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0000634OXYS/Novmale547 days4CMO:0002840neuron golgi apparatus area to neuron cytoplasm area ratioga/cyto1.2%0.040.08MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103651vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0001013WImale547 days4CMO:0002844neuron rough endoplasmic reticulum area to neuron cytoplasm area ratiorer/cyto27.4%0.511.02MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103653vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0000634OXYS/Novmale547 days4CMO:0002844neuron rough endoplasmic reticulum area to neuron cytoplasm area ratiorer/cyto11.2%0.330.66MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103654vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0001013WImale547 days4CMO:0002848neuron vacuole area to neuron cytoplasm area ratiov/cyto3.97%0.340.68MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103656vehicle control condition (for 180 days)
2844Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.neuron morphology traitRS:0000634OXYS/Novmale547 days4CMO:0002848neuron vacuole area to neuron cytoplasm area ratiov/cyto8.23%0.40.8MMO:0000221ex vivo electron microscopy with digital image analysis0.0vehicle control condition (for 180 days)103657vehicle control condition (for 180 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0000760SHRSP/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio4.66g/kg0.4MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102100vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0000761WKY/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio3.48g/kg0.26MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102101vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio4.03g/kg0.28MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102102vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0004553SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrcmale126 days6CMO:0000074heart weight to body weight ratio4.47g/kg0.270.6614MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102103vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0004554SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio3.88g/kg0.12MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102104vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0004555SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrcmale126 days7CMO:0000074heart weight to body weight ratio4.07g/kg0.170.4498MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102105vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio4.26g/kg0.3MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102106vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0004557SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio4.72g/kg0.64MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102107vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0000760SHRSP/Gcrcmale126 days17CMO:0002926urine urea level to urine creatinine level ratio112.6929.95123.487MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)103791vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0000761WKY/Gcrcmale126 days18CMO:0002926urine urea level to urine creatinine level ratio68.859.1138.6505MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)103792vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0002926urine urea level to urine creatinine level ratio87.3312.8138.43MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)103793vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0002926urine urea level to urine creatinine level ratio101.158.4722.4095MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)103794vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0002926urine urea level to urine creatinine level ratio76.344.1410.1409MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)103795vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart massRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 daysN/ACMO:0000074heart weight to body weight ratio4.67g/kg0.4MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102108vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0000760SHRSP/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio3.64mg/g0.39MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102109vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0000761WKY/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio2.52mg/g0.2MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102110vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio3.04mg/g0.29MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102111vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0004553SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrcmale126 days6CMO:0000530heart left ventricle weight to body weight ratio3.33mg/g0.330.8083MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102112vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0004554SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio2.79mg/g0.14MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102113vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0004555SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrcmale126 days7CMO:0000530heart left ventricle weight to body weight ratio3mg/g0.110.291MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102114vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio3.12mg/g0.24MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102115vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0004557SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio3.57mg/g0.66MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102116vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.heart left ventricle massRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 daysN/ACMO:0000530heart left ventricle weight to body weight ratio3.28mg/g0.19MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102117vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0000760SHRSP/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio4.11g/kg0.25MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102118vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0000761WKY/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio2.87g/kg0.23MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102119vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio3.65g/kg0.2MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102120vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0004553SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrcmale126 days6CMO:0000340both kidneys wet weight to body weight ratio3.78g/kg0.180.4409MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102121vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0004554SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio3.77g/kg0.12MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102122vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio4.16g/kg0.4MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102123vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood albumin amountRS:0002216Slc:Wmale105 daysN/ACMO:0002898blood glycated albumin levelglycated albumin n=4-61.5%0.05MMO:0000166blood protein analysis0.0vehicle control condition (for 21 days)102874vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood albumin amountRS:0000482GK/Slcmale105 daysN/ACMO:0002898blood glycated albumin levelglycated albumin n=4-62.3%0.07MMO:0000166blood protein analysis0.0vehicle control condition (for 21 days)102876vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood hemoglobin amountRS:0002216Slc:Wmale105 daysN/ACMO:0002786blood hemoglobin A1c levelHbA1c n=4-65.32%0.13MMO:0000295blood hemoglobin analysis0.0vehicle control condition (for 21 days)102878vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood hemoglobin amountRS:0000482GK/Slcmale105 daysN/ACMO:0002786blood hemoglobin A1c levelHbA1c n=4-65.21%0.12MMO:0000295blood hemoglobin analysis0.0vehicle control condition (for 21 days)102880vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood free fatty acid amountRS:0002216Slc:Wmale105 daysN/ACMO:0000117blood free fatty acids levelueq/l = umol/l9.99485mg/dl0.7204MMO:0000216blood free fatty acid analysis0.0vehicle control condition (for 21 days)102882vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood free fatty acid amountRS:0000482GK/Slcmale105 daysN/ACMO:0000117blood free fatty acids levelueq/l = umol/l12.551475mg/dl0.517MMO:0000216blood free fatty acid analysis0.0vehicle control condition (for 21 days)102884vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood triglyceride amountRS:0002216Slc:Wmale105 daysN/ACMO:0000118blood triglyceride leveln=4-6119.5mg/dl12.4MMO:0000233blood triglyceride analysis0.0vehicle control condition (for 21 days)102886vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood triglyceride amountRS:0000482GK/Slcmale105 daysN/ACMO:0000118blood triglyceride leveln=4-652.3mg/dl7.4MMO:0000233blood triglyceride analysis0.0vehicle control condition (for 21 days)102888vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood cholesterol amountRS:0002216Slc:Wmale105 daysN/ACMO:0000051blood total cholesterol leveln=4-667mg/dl3.5MMO:0000491blood cholesterol analysis0.0vehicle control condition (for 21 days)102890vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood cholesterol amountRS:0000482GK/Slcmale105 daysN/ACMO:0000051blood total cholesterol leveln=4-677.8mg/dl5.2MMO:0000491blood cholesterol analysis0.0vehicle control condition (for 21 days)102892vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood HDL cholesterol amountRS:0002216Slc:Wmale105 daysN/ACMO:0000052blood high density lipoprotein cholesterol leveln=4-64.2mg/dl0.3MMO:0000278blood high-density lipoprotein-cholesterol measurement test0.0vehicle control condition (for 21 days)102894vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood HDL cholesterol amountRS:0000482GK/Slcmale105 daysN/ACMO:0000052blood high density lipoprotein cholesterol leveln=4-69mg/dl0.9MMO:0000278blood high-density lipoprotein-cholesterol measurement test0.0vehicle control condition (for 21 days)102896vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood LDL cholesterol amountRS:0002216Slc:Wmale105 daysN/ACMO:0000053blood low density lipoprotein cholesterol leveln=4-626.8mg/dl1.4MMO:0000279blood low-density lipoprotein-cholesterol measurement test0.0vehicle control condition (for 21 days)102898vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood LDL cholesterol amountRS:0000482GK/Slcmale105 daysN/ACMO:0000053blood low density lipoprotein cholesterol leveln=4-624.3mg/dl1.8MMO:0000279blood low-density lipoprotein-cholesterol measurement test0.0vehicle control condition (for 21 days)102900vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood urea nitrogen amountRS:0002216Slc:Wmale105 daysN/ACMO:0000049blood urea nitrogen leveln=4-619.8mg/dl0.6MMO:0000253blood urea nitrogen analysis0.0vehicle control condition (for 21 days)102902vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood urea nitrogen amountRS:0000482GK/Slcmale105 daysN/ACMO:0000049blood urea nitrogen leveln=4-615.7mg/dl1.2MMO:0000253blood urea nitrogen analysis0.0vehicle control condition (for 21 days)102904vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood creatinine amountRS:0002216Slc:Wmale105 daysN/ACMO:0000538blood creatinine leveln=4-60.33mg/dl0.01MMO:0000270blood creatinine analysis0.0vehicle control condition (for 21 days)102906vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.blood creatinine amountRS:0000482GK/Slcmale105 daysN/ACMO:0000538blood creatinine leveln=4-60.26mg/dl0.02MMO:0000270blood creatinine analysis0.0vehicle control condition (for 21 days)102908vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine ketone body amountRS:0002216Slc:Wmale105 daysN/ACMO:0002897urine acetoacetone leveln=4-650.3umol/l2.6MMO:0000147urine analysis0.0vehicle control condition (for 21 days)102914vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine ketone body amountRS:0000482GK/Slcmale105 daysN/ACMO:0002897urine acetoacetone leveln=4-691.5umol/l39.9MMO:0000147urine analysis0.0vehicle control condition (for 21 days)102916vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine ketone body amountRS:0002216Slc:Wmale105 daysN/ACMO:0002896urine 3-hydroxybutyrate leveln=4-6265.3umol/l11.7MMO:0000147urine analysis0.0vehicle control condition (for 21 days)102918vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine ketone body amountRS:0000482GK/Slcmale105 daysN/ACMO:0002896urine 3-hydroxybutyrate leveln=4-6323.3umol/l92.7MMO:0000147urine analysis0.0vehicle control condition (for 21 days)102920vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine outputRS:0002216Slc:Wmale105 daysN/ACMO:0000260timed urine volumen=4-611.2ml/d0.5MMO:0000357urine volume measurement method0.0vehicle control condition (for 21 days)102922vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine outputRS:0000482GK/Slcmale105 daysN/ACMO:0000260timed urine volumen=4-69.6ml/d0.7MMO:0000357urine volume measurement method0.0vehicle control condition (for 21 days)102924vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine glucose amountRS:0002216Slc:Wmale105 daysN/ACMO:0000383urine glucose leveln=4-631.8mg/dl3.4MMO:0000165blood glucose test strip read by electrochemical glucometer0.0vehicle control condition (for 21 days)102926vehicle control condition (for 21 days)
2781Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.urine glucose amountRS:0000482GK/Slcmale105 daysN/ACMO:0000383urine glucose leveln=4-6588.3mg/dl349.4MMO:0000165blood glucose test strip read by electrochemical glucometer0.0vehicle control condition (for 21 days)102928vehicle control condition (for 21 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0000731WKY/NCrlmale168 days6CMO:0000005diastolic blood pressurenighttime measurement89mmHg3.07.3485MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours)103550vehicle control condition (for 28 days)dark phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.arterial blood pressure traitRS:0001299GKmale168 days6CMO:0000005diastolic blood pressurenighttime measurement104mmHg2.04.899MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours)103552vehicle control condition (for 28 days)dark phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.heart pumping traitRS:0000731WKY/NCrlmale168 days6CMO:0000002heart ratedaytime measurement294beats/min5.012.2474MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours)103558vehicle control condition (for 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.heart pumping traitRS:0001299GKmale168 days6CMO:0000002heart ratedaytime measurement279beats/min3.07.3485MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/day for 4 weeksvehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours)103560vehicle control condition (for 28 days)light phase of controlled light/dark cycle (for 12 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.heart pumping traitRS:0000731WKY/NCrlmale168 days6CMO:0000002heart ratenighttime measurement344beats/min5.012.2474MMO:0000070intra-aortic abdominal radiotelemetrymeasured 12 hr/night for 4 weeksvehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours)103566vehicle control condition (for 28 days)dark phase of controlled light/dark cycle (for 12 hours)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle massRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0002787heart left ventricle weight to tibia length ratiolv/tl0.2g/cm0.0050.015MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101695bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle massRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0002787heart left ventricle weight to tibia length ratiolv/tl0.28g/cm0.0070.0198MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101697bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.retroperitoneal fat pad massRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0002990retroperitoneal fat pad weight to tibia length ratiovf/tl105mg/mm9.027.0MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101699bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.retroperitoneal fat pad massRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0002990retroperitoneal fat pad weight to tibia length ratiovf/tl482mg/mm18.050.9117MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101701bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.inguinal fat pad massRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0002991inguinal fat pad weight to tibia length ratiosf/tl32mg/mm3.09.0MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101703bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.inguinal fat pad massRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0002991inguinal fat pad weight to tibia length ratiosf/tl209mg/mm12.033.9411MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101705bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle wall thicknessRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000987heart ventricle septal wall thickness0.158cm0.0030.009MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101707bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle wall thicknessRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000987heart ventricle septal wall thickness0.205cm0.0040.0113MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101709bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days15CMO:0000082right kidney wet weight1.3533g0.04390.17MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100373left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume10.6ml/d2.25.8207MMO:0000357urine volume measurement method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100376left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.52mg/dl0.040.098MMO:0000306plasma creatinine analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100379left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney integrity traitRS:0000742WKYmale252 days to 238 days15CMO:0001258kidney fibrotic lesion area to total kidney area ratio0.75%0.130.5035MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100385left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney blood vessel morphology traitRS:0000742WKYmale252 days to 238 days15CMO:0002790artery tunica media width to artery inner diameter ratio1.820.150.5809MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100388left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.body massRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000012body weight294g6.018.0MMO:0000016body weighing method0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101661bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.body massRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000012body weight393g6.016.9706MMO:0000016body weighing method0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101663bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.tibia lengthRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0001731tibia straight segment length35.8mm0.41.2MMO:0000209body length measuring method0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101665bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.tibia lengthRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0001731tibia straight segment length32.5mm0.92.5456MMO:0000209body length measuring method0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101667bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.arterial blood pressure traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000004systolic blood pressureundefined138mmHg1.03.0MMO:0000031tail cuff plethysmography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101669bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.arterial blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000004systolic blood pressureundefined221mmHg5.014.1421MMO:0000031tail cuff plethysmography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101671bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart pumping traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000002heart rate380beats/min8.024.0MMO:0000031tail cuff plethysmography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101673bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart pumping traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000002heart rate339beats/min11.031.1127MMO:0000031tail cuff plethysmography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101675bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart massRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0001198heart weight to tibia length ratio0.263g/cm0.0060.018MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101681bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle posterior wall thicknessRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000239heart left ventricle posterior wall thickness1.5mm0.020.06MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101711bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle posterior wall thicknessRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000239heart left ventricle posterior wall thickness2.06mm0.040.1131MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101713bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle end-diastolic diameterRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000982heart left ventricle end-diastolic diameter7.21mm0.210.63MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101715bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle end-diastolic diameterRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000982heart left ventricle end-diastolic diameter7.2mm0.140.396MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101717bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle end-diastolic diameterRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000985heart left ventricle fractional shortening39.8%2.57.5MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101719bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle end-diastolic diameterRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000985heart left ventricle fractional shortening47.7%1.95.374MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101721bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle massRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0001123calculated heart left ventricle weight764mg27.081.0MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101723bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle massRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0001123calculated heart left ventricle weight1114mg35.098.9949MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101725bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle wall thicknessRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000988heart left ventricle relative wall thickness44%2.06.0MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101727bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricle wall thicknessRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000988heart left ventricle relative wall thickness57%2.05.6569MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101729bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart pumping traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0002504E wave deceleration time35.4ms1.23.6MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101731bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart pumping traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0002504E wave deceleration time56.9ms1.85.0912MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101733bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart muscle relaxation traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0001482heart isovolumetric relaxation time24.8ms1.85.4MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101735bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart muscle relaxation traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0001482heart isovolumetric relaxation time43.1ms1.54.2426MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101737bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart pumping traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0002556myocardial performance index0.440.010.03MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101739bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart pumping traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0002556myocardial performance index0.610.030.0849MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101741bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricular blood pressure traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0000606left ventricular end-diastolic blood pressure2.27mmHg0.110.33MMO:0000014vascular transducer tipped catheter0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101743bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricular blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0000606left ventricular end-diastolic blood pressure4.43mmHg0.210.594MMO:0000014vascular transducer tipped catheter0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101745bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricular blood pressure traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0001747time constant of left ventricular pressure decay36.2ms0.51.5MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101747bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricular blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0001747time constant of left ventricular pressure decay47.3ms1.54.2426MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101749bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricular blood pressure traitRS:0004552SS.ZUC-Leprfa+/+/Slcfemale91 days9CMO:0002993heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio0.32mmHg/mm0.020.06MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101751bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart left ventricular blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0002993heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio0.63mmHg/mm0.050.1414MMO:0000337echocardiography0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101753bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricle posterior wall thicknessRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000238heart posterior wall thickness0.206cm0.0060.0216MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)101998vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricle wall thicknessRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000988heart left ventricle relative wall thickness49%1.03.6056MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)102004vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricle end-diastolic diameterRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000985heart left ventricle fractional shortening47.66%2.438.7615MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)102007vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.cardiac output traitRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000180ejection fraction82.5%1.946.9948MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)102010vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.blood flow traitRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0002504E wave deceleration time53.05ms1.485.3362MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)102013vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart muscle relaxation traitRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0001482heart isovolumetric relaxation time40.75ms2.428.7254MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)102016vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricular blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0001747time constant of left ventricular pressure decay33.52ms1.093.9301MMO:0000337echocardiography0.0vehicle control condition (0.5 %) (for 28 days)102019vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricular blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0000606left ventricular end-diastolic blood pressure17.65mmHg1.435.1559MMO:0000014vascular transducer tipped catheter0.0vehicle control condition (0.5 %) (for 28 days)102022vehicle control condition (0.5 %) (for 28 days)
2644Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.heart left ventricular blood pressure traitRS:0004550SS.ZUC-Leprfa-/-/Slcmale91 days13CMO:0002993heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio2.1mmHg/mm0.130.4687MMO:0000014vascular transducer tipped catheter0.0vehicle control condition (0.5 %) (for 28 days)102025vehicle control condition (0.5 %) (for 28 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.heart left ventricle end-diastolic diameterRS:0003328SS/NEisSlcmale126 days8CMO:0000982heart left ventricle end-diastolic diameter8.7mm0.30.8485MMO:0000002transthoracic echocardiography0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102320controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.kidney massRS:0003328SS/NEisSlcmale126 days8CMO:0000340both kidneys wet weight to body weight ratio5.19g/kg0.190.5374MMO:0000005post excision weight measurement0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102323controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.blood creatinine amountRS:0003328SS/NEisSlcmale126 days8CMO:0000057serum creatinine level0.47mg/dl0.040.1131MMO:0000271serum creatinine analysis0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102326controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.blood urea nitrogen amountRS:0003328SS/NEisSlcmale126 days8CMO:0000587serum urea nitrogen level33.6mg/dl4.111.5966MMO:0000274serum urea nitrogen analysis0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102329controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.glomerular filtration traitRS:0003328SS/NEisSlcmale126 days8CMO:0000765creatinine clearance1.9ml/min0.51.4142MMO:0000271serum creatinine analysis0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102332controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.urine outputRS:0003328SS/NEisSlcmale126 days8CMO:0000260timed urine volume53.6ml/d7.120.0818MMO:0000357urine volume measurement method0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102335controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2684Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.total urine protein amountRS:0003328SS/NEisSlcmale126 days8CMO:0000756urine total protein excretion rate307mg/d46.0130.1076MMO:0000334urine protein analysis0.0controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days)102338controlled sodium content diet (0.3 %) (for 42 days)controlled sodium content diet (8 %) (for 77 days)vehicle control condition (for 49 days)
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.arterial blood pressure traitRS:0001366LL/Mavmale56 days9CMO:0000004systolic blood pressuremean of 3 samples of undefined durationserial mean115mmHg5.015.0MMO:0000031tail cuff plethysmography0.0vehicle control condition102702vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.arterial blood pressure traitRS:0000556LH/Mavmale56 days11CMO:0000004systolic blood pressuremean of 3 samples of undefined durationserial mean134mmHg4.013.2665MMO:0000031tail cuff plethysmography0.0vehicle control condition102704vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine outputRS:0001366LL/Mavmale56 days9CMO:0000260timed urine volume9.1ml/d0.41.2MMO:0000357urine volume measurement method0.0vehicle control condition102706vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine outputRS:0000556LH/Mavmale56 days11CMO:0000260timed urine volume8.7ml/d0.30.995MMO:0000357urine volume measurement method0.0vehicle control condition102708vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.total urine protein amountRS:0001366LL/Mavmale56 days9CMO:0000756urine total protein excretion rate26mg/d1.03.0MMO:0000334urine protein analysis0.0vehicle control condition102710vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.total urine protein amountRS:0000556LH/Mavmale56 days11CMO:0000756urine total protein excretion rate70mg/d9.029.8496MMO:0000334urine protein analysis0.0vehicle control condition102712vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood glucose amountRS:0001366LL/Mavmale56 days9CMO:0000046blood glucose level70mg/dl1.03.0MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours)102714vehicle control conditionfasting (for 16 hours)
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.body massRS:0004500SD-Nfe2l2em1Mcwi+/+male11 days to 9 days8CMO:0000012body weight281g17.750.0632MMO:0000016body weighing method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days)100733controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)
2520Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.body massRS:0004501SD-Nfe2l2em1Mcwi-/-male11 days to 9 days4CMO:0000012body weight299g22.244.4MMO:0000016body weighing method0.0controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days)100734controlled sodium content diet (0.4 %) (between 70 and 84 days)controlled sodium content diet (4 %) (for 6 days)vehicle control condition (for 3 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0004555SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrcmale126 days7CMO:0000340both kidneys wet weight to body weight ratio3.77g/kg0.150.3969MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102161vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2761Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.arterial blood pressure traitRS:0000556LH/Mavmale63 days8CMO:0000004systolic blood pressureundefined160mmHg3.08.4853MMO:0000031tail cuff plethysmography0.0vehicle control condition102848vehicle control condition
2761Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.arterial blood pressure traitRS:0000556LH/Mavmale84 days8CMO:0000004systolic blood pressureundefined160mmHgMMO:0000031tail cuff plethysmography0.0vehicle control condition102849vehicle control condition
2761Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.renal blood flow traitRS:0000556LH/Mavmale84 days8CMO:0001955renal blood flow rate to kidney weight ratio5ml/min/g0.30.8485MMO:0000228ultrasonic flowmeter0.0vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) 102853vehicle control conditionketamine (20 mg/kg) thiobutabarbital (75 mg/kg)
2761Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.kidney blood vessel physiology traitRS:0000556LH/Mavmale84 days8CMO:0003218renal vascular resistance to kidney weight ratioSBP/RBF33ml/min/g/mmHg2.05.6569MMO:0000228ultrasonic flowmeter0.0vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) 102857vehicle control conditionketamine (20 mg/kg) thiobutabarbital (75 mg/kg)
2622Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.heart massRS:0004550SS.ZUC-Leprfa-/-/Slcfemale91 days8CMO:0001198heart weight to tibia length ratio0.35g/cm0.00120.0034MMO:0000005post excision weight measurement0.0ovariectomy42daysbilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days)101693bilateral ovariectomy (for 42 days)vehicle control condition (for 35 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0004557SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio4.25g/kg0.7MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102124vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.kidney massRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio4.2g/kg0.62MMO:0000005post excision weight measurement0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102125vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.drinking behavior traitRS:0000760SHRSP/Gcrcmale126 days17CMO:0000741water drink intake rate78.62ml/d21.7989.8425MMO:0000697metabolic cage water drinking measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102126vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.drinking behavior traitRS:0000761WKY/Gcrcmale126 days18CMO:0000741water drink intake rate53.12ml/d30.74130.4188MMO:0000697metabolic cage water drinking measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102127vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.drinking behavior traitRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0000741water drink intake rate58.47ml/d9.4328.29MMO:0000697metabolic cage water drinking measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102128vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.drinking behavior traitRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0000741water drink intake rate57.55ml/d15.2340.2948MMO:0000697metabolic cage water drinking measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102129vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.drinking behavior traitRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0000741water drink intake rate79.16ml/d16.7841.1024MMO:0000697metabolic cage water drinking measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102130vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine outputRS:0000760SHRSP/Gcrcmale126 days17CMO:0000260timed urine volume55.29ml/d15.7865.0626MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102131vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine outputRS:0000761WKY/Gcrcmale126 days18CMO:0000260timed urine volume31.8ml/d14.3460.8395MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102132vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine outputRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0000260timed urine volume34.03ml/d7.0221.06MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102133vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine outputRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0000260timed urine volume30.68ml/d11.3229.9499MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102134vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine outputRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0000260timed urine volume55.86ml/d8.6721.2371MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102135vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine sodium amountRS:0000760SHRSP/Gcrcmale126 days17CMO:0000129urine sodium level211.14mmol/l46.41191.3533MMO:0000434urine sodium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102136vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine sodium amountRS:0000761WKY/Gcrcmale126 days18CMO:0000129urine sodium level220.23mmol/l71.19302.0336MMO:0000434urine sodium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102137vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle wall thicknessRS:0000742WKYmale252 days to 238 days30CMO:0000987heart ventricle septal wall thickness0.1cm0.0040.0219MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100338left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle end-diastolic diameterRS:0000742WKYmale252 days to 238 days30CMO:0000982heart left ventricle end-diastolic diameter10.6mm0.10.5477MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100341left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle end-systolic diameterRS:0000742WKYmale252 days to 238 days30CMO:0000983heart left ventricle end-systolic diameter8.9mm0.21.0954MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100344left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle posterior wall thicknessRS:0000742WKYmale252 days to 238 days30CMO:0000238heart posterior wall thickness0.18cm0.0040.0219MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100347left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle end-diastolic diameterRS:0000742WKYmale252 days to 238 days30CMO:0000985heart left ventricle fractional shortening15.8%0.73.8341MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100350left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.cardiac output traitRS:0000742WKYmale252 days to 238 days30CMO:0000180ejection fraction37%1.47.6681MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100353left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood flow traitRS:0000742WKYmale252 days to 238 days30CMO:0002789E/A wave ratio1.850.140.7668MMO:0000337echocardiography0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100356left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.kidney massRS:0000742WKYmale252 days to 238 days15CMO:0000082right kidney wet weight1.3533g0.04390.17MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100359left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.urine outputRS:0000742WKYmale252 days to 238 days7CMO:0000260timed urine volume10.6ml/d2.25.8207MMO:0000357urine volume measurement method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100362left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.blood creatinine amountRS:0000742WKYmale252 days to 238 days6CMO:0000537plasma creatinine level0.52mg/dl0.040.098MMO:0000306plasma creatinine analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100365left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine sodium amountRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0000129urine sodium level268.97mmol/l32.798.1MMO:0000434urine sodium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102138vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine sodium amountRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0000129urine sodium level260.49mmol/l36.6997.0726MMO:0000434urine sodium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102139vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine sodium amountRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0000129urine sodium level169.89mmol/l27.4667.263MMO:0000434urine sodium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102140vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine potassium amountRS:0000760SHRSP/Gcrcmale126 days17CMO:0000128urine potassium level44.48mmol/l17.3771.6183MMO:0000435urine potassium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102141vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine potassium amountRS:0000761WKY/Gcrcmale126 days18CMO:0000128urine potassium level71.25mmol/l33.04140.1768MMO:0000435urine potassium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102142vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine potassium amountRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0000128urine potassium level72.41mmol/l20.3761.11MMO:0000435urine potassium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102143vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine potassium amountRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0000128urine potassium level80.72mmol/l27.071.4353MMO:0000435urine potassium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102144vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine potassium amountRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0000128urine potassium level28.25mmol/l8.5921.0411MMO:0000435urine potassium analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102145vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0000760SHRSP/Gcrcmale126 days17CMO:0002924urine urea level131.16mmol/l57.62237.5733MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102146vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0000761WKY/Gcrcmale126 days18CMO:0002924urine urea level235.52mmol/l90.62384.4681MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102147vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0002924urine urea level228.93mmol/l62.26186.78MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102148vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0002924urine urea level316.61mmol/l113.57300.478MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102149vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine urea amountRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0002924urine urea level103mmol/l34.2383.846MMO:0000676urine urea analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102150vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine creatinine amountRS:0000760SHRSP/Gcrcmale126 days17CMO:0000125urine creatinine level6.85368mg/dl2.765511.4025MMO:0000275urine creatinine analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102151vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine creatinine amountRS:0000761WKY/Gcrcmale126 days18CMO:0000125urine creatinine level13.90776mg/dl5.290622.4459MMO:0000275urine creatinine analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102152vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine creatinine amountRS:0003568SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrcmale126 days9CMO:0000125urine creatinine level10.4208mg/dl1.80365.4108MMO:0000275urine creatinine analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102153vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine creatinine amountRS:0004556SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrcmale126 days7CMO:0000125urine creatinine level12.38472mg/dl3.60729.5438MMO:0000275urine creatinine analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102154vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2646Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.urine creatinine amountRS:0004558SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrcmale126 days6CMO:0000125urine creatinine level5.37072mg/dl1.5233.7307MMO:0000275urine creatinine analysis0.0vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days)102155vehicle control condition (for 126 days)sodium chloride solution (1 %) (for 21 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.body massRS:0000731WKY/NCrlmale168 days6CMO:0000012body weight463g7.017.1464MMO:0000016body weighing method0.0vehicle control condition (for 28 days)103490vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.body massRS:0001299GKmale168 days6CMO:0000012body weight380g7.017.1464MMO:0000016body weighing method0.0vehicle control condition (for 28 days)103492vehicle control condition (for 28 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.drinking behavior traitRS:0000731WKY/NCrlmale175 days to 140 days6CMO:0002859water intake drink rate to body weight ratio50ml/d/kg1.02.4495MMO:0000619drink intake measuring methodvehicle control condition (between 1 and 35 days)103498vehicle control condition (between 1 and 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.drinking behavior traitRS:0001299GKmale175 days to 140 days6CMO:0002859water intake drink rate to body weight ratio99ml/d/kg13.031.8434MMO:0000619drink intake measuring methodvehicle control condition (between 1 and 35 days)103500vehicle control condition (between 1 and 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.blood fructosamine amountRS:0000731WKY/NCrlmale175 days6CMO:0002856serum fructosamine level153umol/l3.07.3485MMO:0000708serum fructosamine analysis0.0vehicle control condition (for 35 days)103502vehicle control condition (for 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.blood fructosamine amountRS:0001299GKmale175 days6CMO:0002856serum fructosamine level187umol/l9.022.0454MMO:0000708serum fructosamine analysis0.0vehicle control condition (for 35 days)103504vehicle control condition (for 35 days)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.blood glucose amountRS:0000731WKY/NCrlmale168 days6CMO:0000046blood glucose level113mg/dl4.09.798MMO:0000165blood glucose test strip read by electrochemical glucometer0.0vehicle control condition (for 28 days) then fasting (for 16 hours)103510vehicle control condition (for 28 days)fasting (for 16 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.blood glucose amountRS:0001299GKmale168 days6CMO:0000046blood glucose level122mg/dl8.019.5959MMO:0000165blood glucose test strip read by electrochemical glucometer0.0vehicle control condition (for 28 days) then fasting (for 16 hours)103512vehicle control condition (for 28 days)fasting (for 16 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.blood glucose amountRS:0000731WKY/NCrlmale168 days6CMO:0000046blood glucose level125mg/dl3.07.3485MMO:0000113oral glucose tolerance test0.0vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours)103518vehicle control condition (for 28 days)fasting (for 16 hours)glucose (2 g/kg) (for 2 hours)
2827Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.blood glucose amountRS:0001299GKmale168 days6CMO:0000046blood glucose level278mg/dl20.048.9898MMO:0000113oral glucose tolerance test0.0vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours)103520vehicle control condition (for 28 days)fasting (for 16 hours)glucose (2 g/kg) (for 2 hours)
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.body massRS:0001366LL/Mavmale56 days9CMO:0000012body weight231g4.012.0MMO:0000016body weighing method0.0vehicle control condition102698vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.body massRS:0000556LH/Mavmale56 days11CMO:0000012body weight246g4.013.2665MMO:0000016body weighing method0.0vehicle control condition102700vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood glucose amountRS:0001366LL/Mavmale56 days9CMO:0000046blood glucose level136mg/dl4.012.0MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours)102718vehicle control conditionfasting (for 16 hours)glucose (2 g/kg) (for 1 hours)
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.body massRS:0001366LL/Mavmale112 days9CMO:0000012body weight364g6.018.0MMO:0000016body weighing method0.0vehicle control condition102722vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.body massRS:0000556LH/Mavmale112 days11CMO:0000012body weight384g9.029.8496MMO:0000016body weighing method0.0vehicle control condition102724vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood glucose amountRS:0000556LH/Mavmale56 days11CMO:0000046blood glucose level69mg/dl1.03.3166MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours)102716vehicle control conditionfasting (for 16 hours)
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood glucose amountRS:0000556LH/Mavmale56 days11CMO:0000046blood glucose level127mg/dl3.09.9499MMO:0000112blood glucose analysis0.0vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours)102720vehicle control conditionfasting (for 16 hours)glucose (2 g/kg) (for 1 hours)
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.arterial blood pressure traitRS:0001366LL/Mavmale112 days9CMO:0000004systolic blood pressuremean of 3 samples of undefined durationserial mean119mmHg4.012.0MMO:0000031tail cuff plethysmography0.0vehicle control condition102726vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.arterial blood pressure traitRS:0000556LH/Mavmale112 days11CMO:0000004systolic blood pressuremean of 3 samples of undefined durationserial mean160mmHg4.013.2665MMO:0000031tail cuff plethysmography0.0vehicle control condition102728vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine outputRS:0001366LL/Mavmale112 days9CMO:0000260timed urine volume12.4ml/d0.61.8MMO:0000357urine volume measurement method0.0vehicle control condition102730vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine outputRS:0000556LH/Mavmale112 days11CMO:0000260timed urine volume11.6ml/d0.41.3266MMO:0000357urine volume measurement method0.0vehicle control condition102732vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.total urine protein amountRS:0001366LL/Mavmale112 days9CMO:0000756urine total protein excretion rate37mg/d1.03.0MMO:0000334urine protein analysis0.0vehicle control condition102734vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.total urine protein amountRS:0000556LH/Mavmale112 days11CMO:0000756urine total protein excretion rate135mg/d21.069.6491MMO:0000334urine protein analysis0.0vehicle control condition102736vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine albumin amountRS:0001366LL/Mavmale112 days9CMO:0000757urine albumin excretion rate4.4mg/d0.30.9MMO:0000406urine albumin analysis0.0vehicle control condition102738vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine albumin amountRS:0000556LH/Mavmale112 days11CMO:0000757urine albumin excretion rate24mg/d4.615.2565MMO:0000406urine albumin analysis0.0vehicle control condition102740vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine creatinine amountRS:0001366LL/Mavmale112 days9CMO:0000764urine creatinine excretion rate11.1mg/d0.51.5MMO:0000275urine creatinine analysis0.0vehicle control condition102746vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.urine creatinine amountRS:0000556LH/Mavmale112 days11CMO:0000764urine creatinine excretion rate12.9mg/d0.41.3266MMO:0000275urine creatinine analysis0.0vehicle control condition102748vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood cholesterol amountRS:0001366LL/Mavmale112 days9CMO:0000585plasma total cholesterol level62.5482mg/dl4.247112.7413MMO:0000284plasma total cholesterol measurement test0.0vehicle control condition102750vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood cholesterol amountRS:0000556LH/Mavmale112 days11CMO:0000585plasma total cholesterol level90.3474mg/dl7.335924.3304MMO:0000284plasma total cholesterol measurement test0.0vehicle control condition102752vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood triglyceride amountRS:0001366LL/Mavmale112 days9CMO:0000548plasma triglyceride level1.4mmol/l0.110.33MMO:0000234plasma triglyceride analysis0.0vehicle control condition102754vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood triglyceride amountRS:0000556LH/Mavmale112 days11CMO:0000548plasma triglyceride level1.43mmol/l0.160.5307MMO:0000234plasma triglyceride analysis0.0vehicle control condition102756vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood creatinine amountRS:0001366LL/Mavmale112 days9CMO:0000537plasma creatinine level0.501mg/dl0.010.03MMO:0000306plasma creatinine analysis0.0vehicle control condition102758vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.blood creatinine amountRS:0000556LH/Mavmale112 days11CMO:0000537plasma creatinine level0.519mg/dl0.0090.0298MMO:0000306plasma creatinine analysis0.0vehicle control condition102760vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.kidney massRS:0001366LL/Mavmale112 days9CMO:0000340both kidneys wet weight to body weight ratio6.08g/kg0.070.21MMO:0000005post excision weight measurement0.0vehicle control condition102762vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.kidney massRS:0000556LH/Mavmale112 days11CMO:0000340both kidneys wet weight to body weight ratio6.24g/kg0.070.2322MMO:0000005post excision weight measurement0.0vehicle control condition102764vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.heart left ventricle massRS:0001366LL/Mavmale112 days9CMO:0000530heart left ventricle weight to body weight ratio1.88mg/g0.0020.006MMO:0000005post excision weight measurement0.0vehicle control condition102766vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.heart left ventricle massRS:0000556LH/Mavmale112 days11CMO:0000530heart left ventricle weight to body weight ratio2.24mg/g0.0030.0099MMO:0000005post excision weight measurement0.0vehicle control condition102768vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.aorta massRS:0001366LL/Mavmale112 days9CMO:0003216aorta weight to body weight ratio11.2mg/100g0.20.6MMO:0000005post excision weight measurement0.0vehicle control condition102770vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.aorta massRS:0000556LH/Mavmale112 days11CMO:0003216aorta weight to body weight ratio13.5mg/100g0.20.6633MMO:0000005post excision weight measurement0.0vehicle control condition102772vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.glomerular filtration traitRS:0001366LL/Mavmale112 days9CMO:0000765creatinine clearance1.53ml/min0.070.21MMO:0000306plasma creatinine analysis0.0vehicle control condition102774vehicle control condition
2721Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.glomerular filtration traitRS:0000556LH/Mavmale112 days11CMO:0000765creatinine clearance1.6ml/min0.10.3317MMO:0000306plasma creatinine analysis0.0vehicle control condition102776vehicle control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle integrity traitRS:0000742WKYmale252 days to 238 days30CMO:0000687heart left ventricle infarction size to total heart left ventricle size ratio35.8%5.429.577MMO:0000219ex vivo microscopy with digital image analysis0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100264left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale56 days to 42 days30CMO:0000012body weight225g1.89.859MMO:0000016body weighing method0.0lad occlusion0daysleft anterior descending coronary artery occlusion then vehicle control condition100269left anterior descending coronary artery occlusionvehicle control condition
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.body massRS:0000742WKYmale252 days to 238 days30CMO:0000012body weight617g52.0284.8157MMO:0000016body weighing method0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100272left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart massRS:0000742WKYmale252 days to 238 days30CMO:0000017heart weight1.573g0.281.5336MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100278left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.heart left ventricle massRS:0000742WKYmale252 days to 238 days30CMO:0000776heart left ventricle weight0.969g0.0790.4327MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100290left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2460Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.lung massRS:0000742WKYmale252 days to 238 days30CMO:0000097lung wet weight2.134g0.130.712MMO:0000005post excision weight measurement0.0lad occlusion196daysleft anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)100299left anterior descending coronary artery occlusion (for 196 days)vehicle control condition (for 182 days)
2499Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.body massRS:0000681SDfemale0 days13CMO:0000012body weight283.6g3.813.7011MMO:0000016body weighing method0.0unx97dayscontrolled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days)100632controlled calcium content diet (0.6 %) (for 97 days)controlled content diet (0.9 %) (for 97 days)unilateral nephrectomy (for 97 days)vehicle control condition (100 ul) (for 90 days)
2499Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.blood creatinine amountRS:0000681SDfemale0 days13CMO:0000057serum creatinine level1.65mg/dl0.140.5048MMO:0000271serum creatinine analysis0.0unx97dayscontrolled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days)100637controlled calcium content diet (0.6 %) (for 97 days)controlled content diet (0.9 %) (for 97 days)unilateral nephrectomy (for 97 days)vehicle control condition (100 ul) (for 90 days)
2499Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.glomerular filtration traitRS:0000681SDfemale0 days13CMO:0000765creatinine clearance0.3ml/min0.030.1082MMO:0000271serum creatinine analysis0.0unx97dayscontrolled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days)100642controlled calcium content diet (0.6 %) (for 97 days)controlled content diet (0.9 %) (for 97 days)unilateral nephrectomy (for 97 days)vehicle control condition (100 ul) (for 90 days)
2499Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.blood parathyroid hormone amountRS:0000681SDfemale0 days13CMO:0002963serum parathyroid hormone level3496pg/ml862.03107.9852MMO:0000690serum parathyroid hormone analysis0.0unx97dayscontrolled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days)100647controlled calcium content diet (0.6 %) (for 97 days)controlled content diet (0.9 %) (for 97 days)unilateral nephrectomy (for 97 days)vehicle control condition (100 ul) (for 90 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.blood urea nitrogen amountRS:0001381PCK-Pkhd1pck/CrljCrlmale112 days5CMO:0000049blood urea nitrogen level20.6mg/dl1.84.0249MMO:0000253blood urea nitrogen analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100763control condition (for 28 days)vehicle control condition (for 84 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.blood urea nitrogen amountRS:0000064Crl:CD(SD)male112 days5CMO:0000049blood urea nitrogen level19.3mg/dl2.65.8138MMO:0000253blood urea nitrogen analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100764control condition (for 28 days)vehicle control condition (for 84 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.blood creatinine amountRS:0001381PCK-Pkhd1pck/CrljCrlmale112 days5CMO:0000057serum creatinine level0.51mg/dl0.040.0894MMO:0000271serum creatinine analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100765control condition (for 28 days)vehicle control condition (for 84 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.blood creatinine amountRS:0000064Crl:CD(SD)male112 days5CMO:0000057serum creatinine level0.43mg/dl0.030.0671MMO:0000271serum creatinine analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100766control condition (for 28 days)vehicle control condition (for 84 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.total urine protein amountRS:0000064Crl:CD(SD)male112 days5CMO:0000756urine total protein excretion rate36.7mg/d3.57.8262MMO:0000334urine protein analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100768control condition (for 28 days)vehicle control condition (for 84 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.total urine protein amountRS:0001381PCK-Pkhd1pck/CrljCrlmale112 days6CMO:0002758urine protein level to urine creatinine level ratio121.74.1641MMO:0000334urine protein analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100769control condition (for 28 days)vehicle control condition (for 84 days)
2521Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.total urine protein amountRS:0000064Crl:CD(SD)male112 days5CMO:0002758urine protein level to urine creatinine level ratio1.980.310.6932MMO:0000334urine protein analysis0.0control condition (for 28 days) then vehicle control condition (for 84 days)100770control condition (for 28 days)vehicle control condition (for 84 days)
2784Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.arterial blood pressure traitRS:0001299GKmale16 days5CMO:0000009mean arterial blood pressureundefined118mmHg7.015.6525MMO:0000014vascular transducer tipped catheter0.0air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)103025air oxygen content (21 %) (for 28 days)vehicle control condition (0.15 ml) (for 0.1 hours)acetylcholine (5 ug/kg/min) (for 0.1 hours)sodium nitroprusside (5 ug/kg/min) (for 0.1 hours)
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart pumping traitRS:0000811SS/JrHsdMcwimale56 days6CMO:0000002heart rate358beats/min7.9519.4734MMO:0000013vascular fluid filled catheter0.0vehicle control condition106798vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart pumping traitRS:0001480SS-Sod3m1Mcwimale56 days8CMO:0000002heart rate354beats/min12.936.4867MMO:0000013vascular fluid filled catheter0.0vehicle control condition106799vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.arterial blood pressure traitRS:0000811SS/JrHsdMcwimale56 days6CMO:0000004systolic blood pressure115mmHg4.7611.6596MMO:0000013vascular fluid filled catheter0.0vehicle control condition106802vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.arterial blood pressure traitRS:0001480SS-Sod3m1Mcwimale56 days8CMO:0000004systolic blood pressure115mmHg5.2214.7644MMO:0000013vascular fluid filled catheter0.0vehicle control condition106803vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.arterial blood pressure traitRS:0000811SS/JrHsdMcwimale56 days6CMO:0000005diastolic blood pressure84mmHg4.059.9204MMO:0000013vascular fluid filled catheter0.0vehicle control condition106806vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.arterial blood pressure traitRS:0001480SS-Sod3m1Mcwimale56 days8CMO:0000005diastolic blood pressure84.2mmHg4.9614.029MMO:0000013vascular fluid filled catheter0.0vehicle control condition106807vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.arterial blood pressure traitRS:0000811SS/JrHsdMcwimale56 days6CMO:0003285mean aortic pressureMean aortic pressure94.4mmHg4.2710.4593MMO:0000013vascular fluid filled catheter0.0vehicle control condition106810vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.arterial blood pressure traitRS:0001480SS-Sod3m1Mcwimale56 days8CMO:0003285mean aortic pressureMean aortic pressure94.5mmHg5.0214.1987MMO:0000013vascular fluid filled catheter0.0vehicle control condition106811vehicle control condition
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.blood creatinine amountRS:0003328SS/NEisSlcnot specified547 days10CMO:0000537plasma creatinine level0.59049684mg/dl0.04980.1574MMO:0000306plasma creatinine analysis0.0vehicle control condition (for 547.5 days)107421vehicle control condition (for 547.5 days)
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.total urine protein amountRS:0003328SS/NEisSlcnot specified547 days10CMO:0000756urine total protein excretion rate215.9mg/d15.348.3828MMO:0000335urine total protein analysis0.0vehicle control condition (for 547.5 days)107437vehicle control condition (for 547.5 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.total life spanRS:0000775SHRSP/A3Nmale168 days to 147 days25CMO:0003800ratio of deaths related to chronic hypertension to total study population during a period of timeratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800)95%MMO:0000160unspecified method0.0controlled sodium chloride content drinking water (1 %) (for 63 days) and controlled fat content diet (24.5 %) (for 63 days) and vehicle control condition (for 63 days)107518controlled sodium chloride content drinking water (1 %) (for 63 days)controlled fat content diet (24.5 %) (for 63 days)vehicle control condition (for 63 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.total urine protein amountRS:0000775SHRSP/A3Nmale154 days to 119 daysN/ACMO:0000756urine total protein excretion rate127mg/d13.0MMO:0000334urine protein analysis86400.0controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and vehicle control condition (between 35 and 49 days)107520controlled sodium chloride content drinking water (1 %) (between 35 and 49 days)controlled fat content diet (24.5 %) (between 35 and 49 days)vehicle control condition (between 35 and 49 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.body massRS:0000775SHRSP/A3Nmale147 days to 126 daysN/ACMO:0000012body weight254g7.0MMO:0000016body weighing method0.0controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and vehicle control condition (for 42 days)107527controlled sodium chloride content drinking water (1 %) (for 42 days)controlled fat content diet (24.5 %) (for 42 days)vehicle control condition (for 42 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney massRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0000081kidney weight2.65g0.1MMO:0000005post excision weight measurementkidney0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107531controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.body massRS:0001011Crl:WImale112 days10CMO:0000012body weight391.8g17.254.3912MMO:0000016body weighing method0.0vehicle control condition (for 28 days)109387vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.body massRS:0000596MWF/FubRkbmale112 days10CMO:0000012body weight362.8g12.840.4772MMO:0000016body weighing method0.0vehicle control condition (for 28 days)109389vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.tibia lengthRS:0001011Crl:WImale113 days10CMO:0000450tibia length4cm1.03.1623MMO:0000276post excision length measurement0.0vehicle control condition (for 28 days)109395vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.tibia lengthRS:0000596MWF/FubRkbmale113 days10CMO:0000450tibia length4.2cm1.03.1623MMO:0000276post excision length measurement0.0vehicle control condition (for 28 days)109397vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.urine outputRS:0001011Crl:WImale114 days10CMO:0000260timed urine volume11.1ml/d1.34.111MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 28 days)109399vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.urine outputRS:0000596MWF/FubRkbmale114 days10CMO:0000260timed urine volume10.1ml/d0.41.2649MMO:0000511metabolic cage urine volume measurement method0.0vehicle control condition (for 28 days)109401vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.urine albumin amountRS:0001011Crl:WImale114 days10CMO:0000757urine albumin excretion rate0.17mg/d0.010.0316MMO:0000075enzyme linked immunosorbent assay0.0vehicle control condition (for 28 days)109403vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.urine albumin amountRS:0000596MWF/FubRkbmale114 days10CMO:0000757urine albumin excretion rate64.4mg/d5.617.7088MMO:0000075enzyme linked immunosorbent assay0.0vehicle control condition (for 28 days)109405vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.arterial blood pressure traitRS:0001011Crl:WImale112 days10CMO:0000004systolic blood pressure126.9mmHg4.012.6491MMO:0000031tail cuff plethysmography0.0vehicle control condition (10 mg/kg/d) (for 28 days)109407vehicle control condition (10 mg/kg/d) (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.arterial blood pressure traitRS:0000596MWF/FubRkbmale112 days10CMO:0000004systolic blood pressure151.5mmHg9.028.4605MMO:0000031tail cuff plethysmography0.0vehicle control condition (10 mg/kg/d) (for 28 days)109409vehicle control condition (10 mg/kg/d) (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.heart pumping traitRS:0001011Crl:WImale112 days10CMO:0000002heart rate355.3beats/min9.730.6741MMO:0000031tail cuff plethysmographyheart0.0vehicle control condition (for 28 days)109411vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.heart pumping traitRS:0000596MWF/FubRkbmale112 days10CMO:0000002heart rate352.3beats/min7.323.0846MMO:0000031tail cuff plethysmographyheart0.0vehicle control condition (for 28 days)109413vehicle control condition (for 28 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus size traitRS:0000742WKYmale0 days17CMO:0003489kidney glomerular tuft surface area13.2x 10E3 um23.313.6062MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107511unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney integrity traitRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0003443kidney tubule regeneration foci count27.3/section2.9MMO:0000561ex vivo light microscopy with histochemistry0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107547controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney integrity traitRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0003445interstitial nephritis foci count8.5/section1.2MMO:0000561ex vivo light microscopy with histochemistry0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107551controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.blood cholesterol amountRS:0003766WAG/Novmale180 days to 150 days10CMO:0000585plasma total cholesterol level74.4mg/dl4.112.9653MMO:0000284plasma total cholesterol measurement test0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107781vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.blood cholesterol amountRS:0001334ISIAHmale180 days to 150 days10CMO:0000585plasma total cholesterol level59.5mg/dl3.210.1193MMO:0000284plasma total cholesterol measurement test0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107784vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.blood HDL phospholipid amountRS:0003766WAG/Novmale180 days to 150 days10CMO:0001566plasma high density lipoprotein phospholipid level47.1mg/dl4.112.9653MMO:0000282plasma high-density lipoprotein-cholesterol measurement test0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107787vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.blood HDL phospholipid amountRS:0001334ISIAHmale180 days to 150 days10CMO:0001566plasma high density lipoprotein phospholipid level36.2mg/dl2.47.5895MMO:0000282plasma high-density lipoprotein-cholesterol measurement test0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107790vehicle control condition (2 ml/kg) (for 1 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.platelet size traitRS:0001789BDIX/CrCrlmale71 days10CMO:0001350platelet distribution width8.7fl0.15810.5MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107882DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.platelet size traitRS:0001789BDIX/CrCrlmale92 days10CMO:0001350platelet distribution width8.6fl0.03160.1MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107884DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood urea nitrogen amountserum BUNRS:0001789BDIX/CrCrlmale71 days10CMO:0000587serum urea nitrogen level35mg/dl0.56921.8MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107887DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood urea nitrogen amountserum BUNRS:0001789BDIX/CrCrlmale92 days10CMO:0000587serum urea nitrogen level34.5mg/dl0.41111.3MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107889DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days17CMO:0001954left kidney wet weight to body weight ratio9.9mg/g0.72.8862MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107456unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.platelet size traitRS:0001789BDIX/CrCrlmale71 days10CMO:0001348mean platelet volume5.9fl0.03160.1MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107821DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.platelet size traitRS:0001789BDIX/CrCrlmale92 days10CMO:0001348mean platelet volume5.9fl0.06320.2MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107823DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.leukocyte quantityWBCRS:0001789BDIX/CrCrlmale71 days10CMO:0000365total white blood cell count12.9x 1000 cells/ul0.63252.0MMO:0000144automated total white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107826DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.leukocyte quantityWBCRS:0001789BDIX/CrCrlmale92 days10CMO:0000365total white blood cell count10x 1000 cells/ul0.34791.1MMO:0000144automated total white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107828DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood hemoglobin amounthemoglobin, MCH, MCHCRS:0001789BDIX/CrCrlmale71 days10CMO:0000026blood hemoglobin level19.9g/dl0.66412.1MMO:0000295blood hemoglobin analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107831DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood hemoglobin amounthemoglobin, MCH, MCHCRS:0001789BDIX/CrCrlmale92 days10CMO:0000026blood hemoglobin level18.9g/dl0.47431.5MMO:0000295blood hemoglobin analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107833DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney integrity traitRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0003444kidney total tubule cast count349/section45.0MMO:0000561ex vivo light microscopy with histochemistry0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107555controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney integrity traitRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0003446renal fibrosis foci count16.4/section1.4MMO:0000561ex vivo light microscopy with histochemistry0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107559controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.arterial blood pressure traitRS:0003328SS/NEisSlcnot specified547 days10CMO:0000004systolic blood pressure137mmHg3.09.4868MMO:0000011vascular indwelling catheter methodfemoral artery0.0vehicle control condition (for 547.5 days)106791vehicle control condition (for 547.5 days)
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.heart massRS:0003328SS/NEisSlcnot specified547 days10CMO:0000074heart weight to body weight ratio3.2g/kg0.10.3162MMO:0000005post excision weight measurement0.0vehicle control condition (for 547.5 days)106792vehicle control condition (for 547.5 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days17CMO:0000012body weight256g5.020.6155MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107446unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days17CMO:0000074heart weight to body weight ratio3.5g/kg0.10.4123MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107451unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus size traitRS:0000742WKYmale0 days17CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)19.3x 10E3 um24.819.7909MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition107461unilateral nephrectomy (for 150 days)streptozotocin (35 mg/kg) vehicle control condition
3128Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.cone electrophysiology traitRS:0000698Hsd:SDboth0 days4CMO:0003702photopic B wave amplitude of ERG waveformphotopic b-wave ERG51uVMMO:0000616electroretinographycornea0.0subretinal injection30daysvehicle control condition (2 ul) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) 108644vehicle control condition (2 ul) controlled visible light condition (30 cd x s/m2) visible light stimulus (12 cd/m2)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymus massRS:0003766WAG/Novmale180 days to 150 days10CMO:0000612thymus weight to body weight ratio0.77mg/g0.090.2846MMO:0000005post excision weight measurement0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107688vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymus massRS:0001334ISIAHmale180 days to 150 days10CMO:0000612thymus weight to body weight ratio1.95mg/g0.772.435MMO:0000005post excision weight measurement0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107689vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0003766WAG/Novmale180 days to 150 days10CMO:0001843thymocyte count1028.62x10E6/organ146.62463.6532MMO:0000224isolated cell counting method0.0IP injection1daysvehicle control condition (2 ml/kg) (for 1 days)107693vehicle control condition (2 ml/kg) (for 1 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale71 days10CMO:0000025red blood cell count11x 10E6 cells/ul0.41111.3MMO:0000146automated blood cell counting method0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107801DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte size traitMCV, RDW%RS:0001789BDIX/CrCrlmale71 days10CMO:0000038mean corpuscular volume47.5fl0.03160.1MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107806DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte size traitMCV, RDW%RS:0001789BDIX/CrCrlmale92 days10CMO:0000038mean corpuscular volume47.5fl0.18970.6MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107808DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale71 days10CMO:0000037hematocrit52.3%0.94873.0MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107811DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale92 days10CMO:0000037hematocrit51%1.04363.3MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107813DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3128Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.rod electrophysiology traitRS:0000698Hsd:SDboth0 days4CMO:0003706scotopic A wave amplitude of ERG waveformscotopic a-wave ERG142uVMMO:0000616electroretinographycornea0.0subretinal injection30daysvehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) 108642vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours)visible light stimulus (5 cd/m2)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus size traitRS:0000742WKYmale0 days11CMO:0003489kidney glomerular tuft surface area8.7x 10E3 um22.68.6232MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107510unilateral nephrectomy (for 150 days)vehicle control condition
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.spleen morphology traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0002117spleen cell count707.11x10E6/organ150.29475.2587MMO:0000224isolated cell counting method0.0salineIP injection1daysvehicle control condition (2 ml/kg) (for 1 days)107700vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.spleen morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0002117spleen cell count583.56x10E6/organ109.7346.9019MMO:0000224isolated cell counting method0.0salineIP injection1daysvehicle control condition (2 ml/kg) (for 1 days)107703vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.T cell development traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003521apoptotic hypodiploid thymocyte count to total thymocyte count ratio0.45%0.120.3795MMO:0000617flow cytometry method0.0salineIP injection1daysvehicle control condition (2 ml/kg) (for 1 days)107706vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.T cell development traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003523G0 stage diploid thymocyte count to total thymocyte count ratio93.31%0.932.9409MMO:0000617flow cytometry method0.0salineIP injection1daysvehicle control condition (2 ml/kg) (for 1 days)107709vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.T cell development traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003524G2/M stage tetraploid thymocyte count to total thymocyte count ratio2.62%0.290.9171MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107712vehicle control condition (2 ml/kg) (for 1 days)
3098Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2.body massRS:0000967WAGmale0 days16CMO:0000012body weight272.4g3.3513.4MMO:0000016body weighing method0.0cells and vehicle injectedIP injection21daysCC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days)107872CC531 cells (5 X 10E6) (for 21 days)vehicle control condition (1 ml) (for 21 days)
3098Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2.peritoneum integrity traitRS:0000968WAG/OlaHsdmale0 days16CMO:0003554metastatic intraperitoneal tumor weightabdominal lesion weight7.42g0.25251.01MMO:0000344necropsy0.0CC531 cellsIP injection21daysCC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days)107874CC531 cells (5 X 10E6) (for 21 days)vehicle control condition (1 ml) (for 21 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood cholesterol amountserum total cholesterolRS:0001789BDIX/CrCrlmale92 days10CMO:0000363serum total cholesterol level40.5mg/dl1.70765.4MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107894DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood alanine transaminase amountserum alanine aminotransferaseRS:0001789BDIX/CrCrlmale71 days10CMO:0000575serum alanine aminotransferase activity level59.2U/l1.99226.3MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107907DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood alanine transaminase amountserum alanine aminotransferaseRS:0001789BDIX/CrCrlmale92 days10CMO:0000575serum alanine aminotransferase activity level44.8U/l2.94099.3MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107909DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood alkaline phosphatase amountserum alkaline phosphataseRS:0001789BDIX/CrCrlmale71 days10CMO:0000577serum alkaline phosphatase activity level476U/l1.58115.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107912DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood amylase amountserum amylaseRS:0001789BDIX/CrCrlmale71 days10CMO:0003519serum amylase activity level3096U/l32.2552102.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107944DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3128Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.rod electrophysiology traitRS:0000698Hsd:SDboth0 days4CMO:0003705scotopic B wave amplitude of ERG waveformscotopic b-wave ERG338uVMMO:0000616electroretinographycornea0.0subretinal injection30daysvehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) 108640vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours)visible light stimulus (5 cd/m2)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.body massRS:0000742WKYmale0 days11CMO:0000012body weight408g10.033.1662MMO:0000016body weighing method0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107445unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.heart massRS:0000742WKYmale0 days11CMO:0000074heart weight to body weight ratio2.4g/kg0.10.3317MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107450unilateral nephrectomy (for 150 days)vehicle control condition
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale92 days10CMO:0000025red blood cell count10.7x 10E6 cells/ul0.2530.8MMO:0000146automated blood cell counting method0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107803DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.thymus massRS:0000698Hsd:SDfemale84 days10CMO:0000612thymus weight to body weight ratio1.5mg/g0.351.1068MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105884vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.thymus massRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000612thymus weight to body weight ratio1.61mg/g0.190.6008MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105885vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.spleen massRS:0000698Hsd:SDfemale84 days10CMO:0000149spleen weight to body weight ratio0.299%0.0270.0854MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105896vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.spleen massRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000149spleen weight to body weight ratio0.286%0.0220.0696MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105897vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.brain massRS:0000698Hsd:SDfemale84 days10CMO:0000139brain weight to body weight ratio0.742%0.0310.098MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105908vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.brain massRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000139brain weight to body weight ratio0.742%0.0440.1391MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105909vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.ovary massRS:0000698Hsd:SDfemale84 days10CMO:0003019both ovaries weight to body weight ratio0.049%0.0110.0348MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105920vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.ovary massRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0003019both ovaries weight to body weight ratio0.047%0.0070.0221MMO:0000005post excision weight measurementvehicle control condition (5 ml/kg) (for 28 days)105921vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.erythrocyte quantityRS:0000698Hsd:SDfemale84 days10CMO:0000025red blood cell count7.47x 10E6 cells/ul0.210.6641MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105932vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.erythrocyte quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000025red blood cell count7.41x 10E6 cells/ul0.361.1384MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105933vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.blood hemoglobin amountRS:0000698Hsd:SDfemale84 days10CMO:0000026blood hemoglobin level14.05g/dl0.481.5179MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105944vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.blood hemoglobin amountRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000026blood hemoglobin level14.01g/dl0.621.9606MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105945vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.erythrocyte quantityRS:0000698Hsd:SDfemale84 days10CMO:0000037hematocrit43.31%1.494.7118MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105956vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.erythrocyte quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000037hematocrit43.31%1.675.281MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105957vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.erythrocyte size traitRS:0000698Hsd:SDfemale84 days10CMO:0000038mean corpuscular volume57.96fl1.263.9845MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105968vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.erythrocyte size traitRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000038mean corpuscular volume58.44fl0.872.7512MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105969vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.blood hemoglobin amountRS:0000698Hsd:SDfemale84 days10CMO:0000290mean corpuscular hemoglobin18.82pg0.441.3914MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105980vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.blood hemoglobin amountRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000290mean corpuscular hemoglobin18.92pg0.391.2333MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105981vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.blood hemoglobin amountRS:0000698Hsd:SDfemale84 days10CMO:0000291mean corpuscular hemoglobin concentration32.48g/dl0.682.1503MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105992vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.blood hemoglobin amountRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000291mean corpuscular hemoglobin concentration32.37g/dl0.72.2136MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)105993vehicle control condition (5 ml/kg) (for 28 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.platelet size traitRS:0001789BDIX/CrCrlmale71 days10CMO:0003526platelet distribution width (percentage)5.2%0.00.0MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 108146DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.platelet size traitRS:0001789BDIX/CrCrlmale92 days10CMO:0003526platelet distribution width (percentage)8.5%0.00.0MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 108148DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.vasodilation traitRS:0001011Crl:WImale114 days10CMO:0000731acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel90.3%1.23.7947MMO:0000342wire myographymesenteric artery0.0vehicle control condition (for 28 days)109431vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.vasodilation traitRS:0000596MWF/FubRkbmale114 days10CMO:0000731acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel82.3%3.09.4868MMO:0000342wire myographymesenteric artery0.0vehicle control condition (for 28 days)109433vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.vasoconstriction traitRS:0001011Crl:WImale114 days10CMO:0003726norepinephrine-induced blood vessel contractile force expressed as percent of force of contraction to KCL51.3%4.714.8627MMO:0000342wire myography0.0vehicle control condition (for 28 days)109439vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.vasoconstriction traitRS:0000596MWF/FubRkbmale114 days10CMO:0003726norepinephrine-induced blood vessel contractile force expressed as percent of force of contraction to KCL77.8%10.232.2552MMO:0000342wire myography0.0vehicle control condition (for 28 days)109441vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.vasoconstriction traitRS:0001011Crl:WImale114 days10CMO:0003727negative logarithm of the molar concentration of norepinephrine at which the force of blood vessel contraction is half the maximum value6.70.10.3162MMO:0000342wire myography0.0vehicle control condition (for 28 days)109443vehicle control condition (for 28 days)
3140Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.vasoconstriction traitRS:0000596MWF/FubRkbmale114 days10CMO:0003727negative logarithm of the molar concentration of norepinephrine at which the force of blood vessel contraction is half the maximum value6.90.10.3162MMO:0000342wire myography0.0vehicle control condition (for 28 days)109445vehicle control condition (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.platelet quantityRS:0000698Hsd:SDfemale84 days10CMO:0000029platelet count1308.4x 1000 cells/ul220.08695.9541MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106004vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.platelet quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000029platelet count1388x 1000 cells/ul216.06683.2417MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106005vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.leukocyte quantityRS:0000698Hsd:SDfemale84 days10CMO:0000027white blood cell count9.42x 1000 cells/ul2.257.1151MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106016vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.leukocyte quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000027white blood cell count10.8x 1000 cells/ul1.54.7434MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106017vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.neutrophil quantityRS:0000698Hsd:SDfemale84 days10CMO:0000030blood neutrophil count1.48x 1000 cells/ul0.852.6879MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106028vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.neutrophil quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000030blood neutrophil count1.89x 1000 cells/ul0.621.9606MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106029vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.lymphocyte quantityRS:0000698Hsd:SDfemale84 days10CMO:0000031blood lymphocyte count7.36x 1000 cells/ul1.775.5972MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106040vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.lymphocyte quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000031blood lymphocyte count8.25x 1000 cells/ul1.314.1426MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106041vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.monocyte quantityRS:0000698Hsd:SDfemale84 days10CMO:0000032blood monocyte count0.29x 1000 cells/ul0.140.4427MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106052vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.monocyte quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000032blood monocyte count0.31x 1000 cells/ul0.090.2846MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106053vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.eosinophil quantityRS:0000698Hsd:SDfemale84 days10CMO:0000033blood eosinophil count0.13x 1000 cells/ul0.140.4427MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106064vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.eosinophil quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000033blood eosinophil count0.18x 1000 cells/ul0.180.5692MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106065vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.basophil quantityRS:0000698Hsd:SDfemale84 days10CMO:0000034blood basophil count0.07x 1000 cells/ul0.030.0949MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106076vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.basophil quantityRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000034blood basophil count0.08x 1000 cells/ul0.020.0632MMO:0000174automated hematology analysisvehicle control condition (5 ml/kg) (for 28 days)106077vehicle control condition (5 ml/kg) (for 28 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood cholesterol amountserum total cholesterolRS:0001789BDIX/CrCrlmale71 days10CMO:0000363serum total cholesterol level60mg/dl2.21367.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107892DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood alkaline phosphatase amountserum alkaline phosphataseRS:0001789BDIX/CrCrlmale92 days10CMO:0000577serum alkaline phosphatase activity level620U/l7.273223.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107914DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0003766WAG/Novmale180 days to 150 days10CMO:0003517CD3+ thymocyte countcd3+ thymocyte1021.26x10E6/organ145.57460.3328MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107715vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0003766WAG/Novmale180 days to 150 days10CMO:0003527CD4+CD8- thymocyte countcd4+cd8- t-cell239.75x 10E6/organ50.38159.3155MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107718vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0003766WAG/Novmale180 days to 150 days10CMO:0003528CD4+CD8+ thymocyte countcd4+cd8+ t-cell596.53x10E6/organ88.59280.1462MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107721vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0003766WAG/Novmale180 days to 150 days10CMO:0003529CD4-CD8+ thymocyte countcd4-cd8+ t-cell74.18x10E6/organ11.9737.8525MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107724vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0003766WAG/Novmale180 days to 150 days10CMO:0003530CD4+CD25+ thymocyte countcd4+cd25+ t-cell40.63x10E6/organ7.7724.5709MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107727vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003537CD4+CD25- splenocyte count to total splenocyte count ratiocd4+cd25- spleen27.9%0.692.182MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107730vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003539CD3+ splenocyte count to total splenocyte count ratiocd3- spleen30.13%0.752.3717MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107733vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003540CD11b/c+ splenocyte count to total splenocyte count ratiocd11b/c+ spleen12.4%0.812.5614MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107736vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0003766WAG/Novmale180 days to 150 days10CMO:0003534CD11b/c+ splenocyte countcd11b/c+ spleen92.63x10E6/organ24.2876.7801MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107739vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003538CD4+CD25+ splenocyte count to total splenocyte count ratiocd4+cd25+ spleen1.7%0.170.5376MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107742vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003541CD45RA+ splenocyte count to total splenocyte count ratiocd45 RA+ spleen34.86%1.364.3007MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107745vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003540CD11b/c+ splenocyte count to total splenocyte count ratiocd11b/c+ spleen8.4%1.113.5101MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107748vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003531CD4+CD25+ splenocyte countcd4+cd25+ spleen9.83x10E6/organ0.942.9725MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107751vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003542CD4-CD25+ splenocyte countcd4-cd25+ spleen3.21x 10E6/organ0.571.8025MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107754vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003533CD3+ splenocyte countcd3+ spleen214.09x10E6/organ11.4936.3346MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107757vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.splenocyte morphology traitRS:0001334ISIAHmale180 days to 150 days10CMO:0003534CD11b/c+ splenocyte countcd11b/c+ spleen50.17x10E6/organ10.6533.6783MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107760vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0001334ISIAHmale180 days to 150 days10CMO:0003517CD3+ thymocyte countcd3+ thymus716.82x10E6/organ91.79290.2655MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107763vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0001334ISIAHmale180 days to 150 days10CMO:0003528CD4+CD8+ thymocyte countcd4+cd8+ t-cell419x10E6/organ50.57159.9164MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107766vehicle control condition (2 ml/kg) (for 1 days)
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.urine outputRS:0003328SS/NEisSlcnot specified547 days10CMO:0001968timed urine volume to body weight ratio0.0218736ul/min/g0.00240.0075MMO:0000357urine volume measurement method0.0vehicle control condition (for 547.5 days)107429vehicle control condition (for 547.5 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood triglyceride amountserum triglyceride levelRS:0001789BDIX/CrCrlmale92 days10CMO:0000360serum triglyceride level249mg/dl6.95722.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107899DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.retina blood vessel morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003187retinal uptake index of quinidinequinidine uptake index212%13.022.5167MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106114tritiated quinidine (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.retina blood vessel morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003184retinal uptake index of digoxindigoxin uptake index24%5.810.0459MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106117tritiated digoxin (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.retina blood vessel morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003178retinal uptake index of verapamilverapamil uptake index336%7.012.1244MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106120tritiated verapamil (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.retina blood vessel morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003187retinal uptake index of quinidinequinidine uptake index227%25.043.3013MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106123tritiated quinidine (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.retina blood vessel morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003184retinal uptake index of digoxindigoxin uptake index88%29.751.4419MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106126tritiated digoxin (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.retina blood vessel morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003178retinal uptake index of verapamilverapamil uptake index536%6.010.3923MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106129tritiated verapamil (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.aqueous humor morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003185aqueous humor uptake index of quinidinequinidine uptake index5.95%0.380.6582MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106132tritiated quinidine (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.aqueous humor morphology traitRS:0004432SD-Abcb1aem1Sage-/-male49 days to 35 days3CMO:0003182aqueous humor uptake index of digoxindigoxin uptake index55.9%13.222.8631MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106144tritiated digoxin (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.aqueous humor morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003179aqueous humor uptake index of verapamilverapamil uptake index24.8%1.42.4249MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106147tritiated verapamil (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.blood-brain barrier morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003186brain uptake index of quinidinequinidine uptake index2.12%0.120.2078MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106150tritiated quinidine (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.blood-brain barrier morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003183brain uptake index of digoxindigoxin uptake index0.987%0.350.6062MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106153tritiated digoxin (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.blood-brain barrier morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003177brain uptake index of verapamilverapamil uptake index9.07%0.891.5415MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106156tritiated verapamil (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.blood-brain barrier morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003186brain uptake index of quinidinequinidine uptake index26.1%2.44.1569MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition106159tritiated quinidine (10 uCi) (for 0 hours)vehicle control condition
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.glomerular filtration traitRS:0003328SS/NEisSlcnot specified547 days10CMO:0001211creatinine clearance to body weight ratio0.38241ml/min/100g0.02670.0843MMO:0000306plasma creatinine analysis0.0vehicle control condition (for 547.5 days)107441vehicle control condition (for 547.5 days)
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.locomotor behavior traitRS:0003328SS/NEisSlcnot specified236 days to 63 days10CMO:0001037time to first movement outside a discrete space in an experimental apparatus235s50.0158.1139MMO:0000725passive avoidance test using a two-way shuttle box apparatus0.0passive avoidance test using a two-way shuttle box apparatus (MMO:000072)electric foot shock18daysvehicle control condition (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours)107468vehicle control condition (for 547.5 days)tactile electric shock exposure (500 mA) (for 0 hours)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood bilirubin amountserum bilirubinRS:0001789BDIX/CrCrlmale71 days10CMO:0000376serum total bilirubin level0.4mg/dl0.03160.1MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107924DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood bilirubin amountserum bilirubinRS:0001789BDIX/CrCrlmale92 days10CMO:0000376serum total bilirubin level0.35mg/dl0.15810.5MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107926DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood lactate dehydrogenase amountRS:0001789BDIX/CrCrlmale71 days10CMO:0000668serum lactate dehydrogenase activity level964U/l31.306599.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107929DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood lactate dehydrogenase amountRS:0001789BDIX/CrCrlmale92 days10CMO:0000668serum lactate dehydrogenase activity level2717U/l163.1735516.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107931DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3015Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.blood interleukin-4 amountRS:0000681SDnot specified0 days4CMO:0003066serum interleukin-4 levelerror not defined0.14ug/l0.0050.01MMO:0000075enzyme linked immunosorbent assay0.0vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days)105411vehicle control conditionacetic acid (for 0 hours)physical restraint in tube type rodent restrainer (for 2 hours)fasting (for 1 days)
3015Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.blood interleukin-9 amountRS:0000681SDnot specified0 days4CMO:0003068serum interleukin-9 levelerror not defined0.1ug/l0.0050.01MMO:0000075enzyme linked immunosorbent assay0.0vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days)105415vehicle control conditionacetic acid (for 0 hours)physical restraint in tube type rodent restrainer (for 2 hours)fasting (for 1 days)
3015Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.intestine trypsin amountRS:0000681SDnot specified0 days4CMO:0003072intestine trypsin levelerror not defined0.17ug/l0.0050.01MMO:0000075enzyme linked immunosorbent assay0.0vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days)105419vehicle control conditionacetic acid (for 0 hours)physical restraint in tube type rodent restrainer (for 2 hours)fasting (for 1 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal outer nuclear layer morphology traitRS:0000064Crl:CD(SD)male66 days to 59 days5CMO:0003086retinal outer nuclear layer thicknessouter nuc layer41um1.1182.5MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0vehicle control condition (0 mg/kg) (for 5 days)105434vehicle control condition (0 mg/kg) (for 5 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male66 days to 59 days5CMO:0003083retinal outer layer thicknessouter retinal layer142.2um2.68336.0MMO:0000696optical coherence tomography0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 5 days)105466vehicle control condition (0 mg/kg) (for 5 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male74 days to 67 days5CMO:0003083retinal outer layer thicknessouter retinal layer138.5um3.39887.6MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 13 days)105474vehicle control condition (0 mg/kg) (for 13 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male87 days to 80 days10CMO:0003083retinal outer layer thicknessouter retinal layer136um3.48837.8MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 26 days)105482vehicle control condition (0 mg/kg) (for 26 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.liver massRS:0000698Hsd:SDfemale84 days10CMO:0000141liver weight as percentage of body weight3.647%0.1990.6293MMO:0000005post excision weight measurement0.0vehicle control condition (5 ml/kg) (for 28 days)105720vehicle control condition (5 ml/kg) (for 28 days)
3021Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.liver massRS:0004674SD-Ahrem2Sagefemale84 days10CMO:0000141liver weight as percentage of body weight3.428%0.30.9487MMO:0000005post excision weight measurement0.0vehicle control condition (5 ml/kg) (for 28 days)105726vehicle control condition (5 ml/kg) (for 28 days)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.blood-brain barrier morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003183brain uptake index of digoxindigoxin uptake index14%7.312.644MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition106162tritiated digoxin (10 uCi) (for 0 hours)vehicle control condition
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.blood-brain barrier morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003177brain uptake index of verapamilverapamil uptake index75%5.810.0459MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition106165tritiated verapamil (10 uCi) (for 0 hours)vehicle control condition
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.blood enzyme amountRS:0003328SS/NEisSlcnot specified547 days10CMO:0003487serum NAG activity levelserum NAG activity level (CMO:0003487)20.1uU/ml1.96.0083MMO:0000723blood NAG activity assay0.0blood NAG activity assay (MMO:0000723)vehicle control condition (for 547.5 days)107425vehicle control condition (for 547.5 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0001334ISIAHmale180 days to 150 days10CMO:0003529CD4-CD8+ thymocyte countcd4-cd8+ t-cell63.99x10E6/organ6.2519.7642MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107769vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.thymocyte quantityRS:0001334ISIAHmale180 days to 150 days10CMO:0003530CD4+CD25+ thymocyte countcd4+cd25+ t-cell32.19x10E6/organ7.1522.6103MMO:0000617flow cytometry method0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107772vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.blood triglyceride amountRS:0003766WAG/Novmale180 days to 150 days10CMO:0000548plasma triglyceride level1.1865mmol/l0.09150.2894MMO:0000234plasma triglyceride analysis0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107775vehicle control condition (2 ml/kg) (for 1 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.blood triglyceride amountRS:0001334ISIAHmale180 days to 150 days10CMO:0000548plasma triglyceride level1.2995mmol/l0.11530.3645MMO:0000234plasma triglyceride analysis0.0salineIP injeciton1daysvehicle control condition (2 ml/kg) (for 1 days)107778vehicle control condition (2 ml/kg) (for 1 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal outer nuclear layer morphology traitRS:0000064Crl:CD(SD)male88 days to 81 days5CMO:0003086retinal outer nuclear layer thicknessouter nuc layer53.4um2.32555.2MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0vehicle control condition (0 mg/kg) (for 25 days)105442vehicle control condition (0 mg/kg) (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal outer nuclear layer morphology traitRS:0000064Crl:CD(SD)male144 days to 137 days5CMO:0003085retinal outer nuclear layer photoreceptor nucleus countnuclei per cell10.50.40250.9MMO:0000561ex vivo light microscopy with histochemistry0.0vehicle control condition (for 25 days)105462vehicle control condition (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male87 days to 80 days10CMO:0003084retinal inner layer thicknessinner retinal layer126um4.02499.0MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 26 days)105486vehicle control condition (0 mg/kg) (for 26 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male118 days to 111 days5CMO:0003083retinal outer layer thicknessouter retinal layer132.2um3.71198.3MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 25 days)105490vehicle control condition (0 mg/kg) (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male143 days to 136 days5CMO:0003083retinal outer layer thicknessouter retinal layer129.8um4.02499.0MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 25 days)105498vehicle control condition (0 mg/kg) (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male143 days to 136 days5CMO:0003084retinal inner layer thicknessinner retinal layer123.8um4.829910.8MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 25 days)105502vehicle control condition (0 mg/kg) (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male66 days to 59 days5CMO:0003082full retina thicknessfull retina layer129.7um3.71198.3MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0vehicle control condition (0 mg/kg) (for 5 days)105438vehicle control condition (0 mg/kg) (for 5 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal outer nuclear layer morphology traitRS:0000064Crl:CD(SD)male88 days to 81 days5CMO:0003085retinal outer nuclear layer photoreceptor nucleus countnuclei per cell11.30.37120.83MMO:0000561ex vivo light microscopy with histochemistry0.0vehicle control condition (0 mg/kg) (for 25 days)105450vehicle control condition (0 mg/kg) (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal outer nuclear layer morphology traitRS:0000064Crl:CD(SD)male144 days to 137 days5CMO:0003086retinal outer nuclear layer thicknessouter nuc layer50.6um1.613.6MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0vehicle control condition (for 25 days)105454vehicle control condition (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male144 days to 137 days5CMO:0003082full retina thicknessfull retina layer191.6um7.557916.9MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0vehicle control condition (0 mg/kg) (for 25 days)105458vehicle control condition (0 mg/kg) (for 25 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male66 days to 59 days5CMO:0003084retinal inner layer thicknessinner retinal layer131.6um4.874610.9MMO:0000696optical coherence tomography0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 5 days)105470vehicle control condition (0 mg/kg) (for 5 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male74 days to 67 days5CMO:0003084retinal inner layer thicknessinner retinal layer128.7um4.919311.0MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 13 days)105478vehicle control condition (0 mg/kg) (for 13 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male118 days to 111 days5CMO:0003084retinal inner layer thicknessinner retinal layer121.9um4.38279.8MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0optical coherence tomographyvehicle control condition (0 mg/kg) (for 25 days)105494vehicle control condition (0 mg/kg) (for 25 days)
3029Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.cerebrum integrity traitRS:0001696F344-Pde4dTn(sb-T2/Bart3)2.285Mcwimale0 days6CMO:0003169cerebrum infarct volume to total cerebrum volume ratio20%9.022.0454MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0cerebral ischemia1daysisoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours)106360isoflurane (1.5 %) (for 4 hours)vehicle control conditionmiddle cerebral artery occlusion (for 1 hours)
3015Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.blood immunoglobulin E amountRS:0000681SDnot specified0 days4CMO:0001542serum total immunoglobulin E levelerror not defined0.2ug/l0.00.0MMO:0000075enzyme linked immunosorbent assay0.0vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days)105407vehicle control conditionacetic acid (for 0 hours)physical restraint in tube type rodent restrainer (for 2 hours)fasting (for 1 days)
3016Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.retinal layer morphology traitRS:0000064Crl:CD(SD)male88 days to 81 days5CMO:0003082full retina thicknessfull retina layer177.2um6.216313.9MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0vehicle control condition (0 mg/kg) (for 25 days)105446vehicle control condition (0 mg/kg) (for 25 days)
3018Westlund KN, et al., Neuroscience. 2014 Mar 14;262:165-75. doi: 10.1016/j.neuroscience.2013.12.043. Epub 2014 Jan 3.voluntary movement traitRS:0000215F344male0 days4CMO:0003680measurement of the 50% threshold of mechanical stimulus needed to elicit evasive reactionboth paws2.88g0.440.88MMO:0000752von Frey assay1500.0von Frey assay (MMO:0000752)vehicle control condition105566vehicle control condition
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.life span traitRS:0002538SHRSP/A3NCrlmale175 days to 161 days12CMO:0003630ratio of survivors of severe albuminuria to total study population during a period of timeratio of survivors of severe albuminuria to total study population during a period of time (CMO:0003630)50%MMO:0000160unspecified method0.0controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days)109030controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (for 35 days)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.aqueous humor morphology traitRS:0000681SDmale49 days to 35 days3CMO:0003179aqueous humor uptake index of verapamilverapamil uptake index8.46%0.611.0566MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106138tritiated verapamil (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3028Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.aqueous humor morphology traitRS:0004432SD-Abcb1aem1Sage-/-male56 days to 42 days3CMO:0003185aqueous humor uptake index of quinidinequinidine uptake index12%0.61.0392MMO:0000238liquid scintillation counting0.0sec post excisioncarotid injection15tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours)106141tritiated quinidine (10 uCi) (for 0 hours)vehicle control condition (for 0 hours)
3029Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.cerebrum integrity traitRS:0001013WImale0 days16CMO:0003169cerebrum infarct volume to total cerebrum volume ratio23%3.012.0MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0cerebral ischemia1daysisoflurane (1.5 %) (for 4 hours) then vehicle control condition then Embolism injection at middle cerebral artery (for 1 days)106358isoflurane (1.5 %) (for 4 hours)vehicle control conditionEmbolism injection at middle cerebral artery (for 1 days)
3029Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.cerebrum integrity traitRS:0000215F344male0 days18CMO:0003169cerebrum infarct volume to total cerebrum volume ratio11%2.08.4853MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0cerebral ischemia1daysisoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours)106172isoflurane (1.5 %) (for 4 hours)vehicle control conditionmiddle cerebral artery occlusion (for 1 hours)
3029Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.cerebrum integrity traitRS:0000215F344male0 days6CMO:0003169cerebrum infarct volume to total cerebrum volume ratio18%6.014.6969MMO:0000560ex vivo light microscopy with histochemistry and digital image analysis0.0cerebral ischemia1daysisoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours)106361isoflurane (1.5 %) (for 4 hours)vehicle control conditionmiddle cerebral artery occlusion (for 1 hours)
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003280heart right ventricle weight to left ventricle plus septum weight ratioheart right ventricle weight to left ventricle plus septum weight ratio0.25g/g0.020.0529MMO:0000005post excision weight measurement0.0vehicle control condition106536vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003280heart right ventricle weight to left ventricle plus septum weight ratioheart right ventricle weight to left ventricle plus septum weight ratio0.25g/g0.010.0316MMO:0000005post excision weight measurement0.0vehicle control condition106537vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000776heart left ventricle weight0.641g0.01930.0511MMO:0000005post excision weight measurement0.0vehicle control condition106538vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000776heart left ventricle weight0.64g0.00940.0297MMO:0000005post excision weight measurement0.0vehicle control condition106539vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000777heart right ventricle weight0.162g0.00670.0177MMO:0000005post excision weight measurement0.0vehicle control condition106540vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000777heart right ventricle weight0.157g0.00280.0089MMO:0000005post excision weight measurement0.0vehicle control condition106541vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.body massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000012body weight261g6.015.8745MMO:0000016body weighing method0.0vehicle control condition106550vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.body massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000012body weight259g2.88.8544MMO:0000016body weighing method0.0vehicle control condition106551vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.tibia lengthRS:0000811SS/JrHsdMcwimale56 days7CMO:0000450tibia length3.64cm0.060.1587MMO:0000276post excision length measurement0.0vehicle control condition106554vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.tibia lengthRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000450tibia length3.64cm0.030.0949MMO:0000276post excision length measurement0.0vehicle control condition106555vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.lung massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000096lung weight1.23g0.050.1323MMO:0000005post excision weight measurement0.0vehicle control condition106558vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.lung massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000096lung weight1.2g0.010.0316MMO:0000005post excision weight measurement0.0vehicle control condition106559vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000336right atrium weight0.0161g0.00120.0032MMO:0000005post excision weight measurement0.0vehicle control condition106562vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000336right atrium weight0.0149g0.00110.0036MMO:0000005post excision weight measurement0.0vehicle control condition106563vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000335left atrium weight0.0148g7.0E-40.0019MMO:0000005post excision weight measurement0.0vehicle control condition106566vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000335left atrium weight0.0164g0.00110.0035MMO:0000005post excision weight measurement0.0vehicle control condition106567vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003191heart right atrium weight to left atrium weight ratio1.090.090.2381MMO:0000005post excision weight measurement0.0vehicle control condition106570vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003191heart right atrium weight to left atrium weight ratio0.940.090.2846MMO:0000005post excision weight measurement0.0vehicle control condition106571vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.liver massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000092liver weight10.6g0.421.1112MMO:0000005post excision weight measurement0.0vehicle control condition106574vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.liver massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000092liver weight10.6g0.220.6957MMO:0000005post excision weight measurement0.0vehicle control condition106575vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.kidney massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000081kidney weight2.13g0.050.1323MMO:0000005post excision weight measurement0.0vehicle control condition106578vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.kidney massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000081kidney weight2.03g0.030.0949MMO:0000005post excision weight measurement0.0vehicle control condition106579vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000914heart right ventricle weight to body weight ratio0.62mg/g0.030.0794MMO:0000005post excision weight measurement0.0vehicle control condition106582vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000914heart right ventricle weight to body weight ratio0.61mg/g0.010.0316MMO:0000005post excision weight measurement0.0vehicle control condition106583vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000530heart left ventricle weight to body weight ratio2.43mg/g0.050.1323MMO:0000005post excision weight measurement0.0vehicle control condition106586vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000530heart left ventricle weight to body weight ratio2.49mg/g0.030.0949MMO:0000005post excision weight measurement0.0vehicle control condition106587vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.lung massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000156lung weight to body weight ratio0.403%0.0760.2011MMO:0000005post excision weight measurement0.0vehicle control condition106590vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.lung massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000156lung weight to body weight ratio0.465%0.0070.0221MMO:0000005post excision weight measurement0.0vehicle control condition106591vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0002952heart right atrium weight to body weight ratio0.06mg/g0.010.0265MMO:0000005post excision weight measurement0.0vehicle control condition106594vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0002952heart right atrium weight to body weight ratio0.06mg/g0.010.0316MMO:0000005post excision weight measurement0.0vehicle control condition106595vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0002950heart left atrium weight to body weight ratio0.06mg/g0.010.0265MMO:0000005post excision weight measurement0.0vehicle control condition106598vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0002950heart left atrium weight to body weight ratio0.06mg/g0.010.0316MMO:0000005post excision weight measurement0.0vehicle control condition106599vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.liver massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000633liver weight to body weight ratio40.5g/kg1.022.6987MMO:0000005post excision weight measurement0.0vehicle control condition106602vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.liver massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000633liver weight to body weight ratio40.9g/kg0.772.435MMO:0000005post excision weight measurement0.0vehicle control condition106603vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.kidney massRS:0000811SS/JrHsdMcwimale56 days7CMO:0000622single kidney wet weight to body weight ratio8.14g/kg0.110.291MMO:0000005post excision weight measurement0.0vehicle control condition106606vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.kidney massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0000622single kidney wet weight to body weight ratio7.83g/kg0.150.4743MMO:0000005post excision weight measurement0.0vehicle control condition106607vehicle control condition
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.arterial blood pressure traitRS:0000775SHRSP/A3Nmale189 days to 168 days6CMO:0000004systolic blood pressureserial mean284mmHg8.019.5959MMO:0000031tail cuff plethysmographytail0.0average 3 week intervals for 12 weekscontrolled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and vehicle control condition (for 84 days)107499controlled sodium chloride content drinking water (1 %) (for 84 days)controlled fat content diet (24.5 %) (for 84 days)vehicle control condition (for 84 days)
3096Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.leukocyte quantityRS:0001334ISIAHmale180 days to 150 days10CMO:0002340blood non-specified leukocyte count2.9610E3/ul0.993.1307MMO:0000533white blood cell counting method0.0salineIP injection1daysvehicle control condition (2 ml/kg) (for 1 days)107696vehicle control condition (2 ml/kg) (for 1 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney massRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0000340both kidneys wet weight to body weight ratio13g/kg0.7MMO:0000005post excision weight measurementkidney0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107535controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
3090Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.kidney glomerulus integrity traitRS:0000775SHRSP/A3Nmale182 days to 126 daysN/ACMO:0003447kidney glomerular lesion count76.5/section7.0MMO:0000561ex vivo light microscopy with histochemistryrenal glomerulus0.0controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days)107539controlled sodium chloride content drinking water (1 %) (between 42 and 77 days)controlled fat content diet (24.5 %) (between 42 and 77 days)vehicle control condition (between 42 and 77 days)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood hemoglobin amounthemoglobin, MCH, MCHCRS:0001789BDIX/CrCrlmale71 days10CMO:0000290mean corpuscular hemoglobin18pg0.06320.2MMO:0000295blood hemoglobin analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107836DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood hemoglobin amounthemoglobin, MCH, MCHCRS:0001789BDIX/CrCrlmale92 days10CMO:0000290mean corpuscular hemoglobin17.5pg0.03160.1MMO:0000295blood hemoglobin analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107838DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood hemoglobin amounthemoglobin, MCH, MCHCRS:0001789BDIX/CrCrlmale71 days10CMO:0000291mean corpuscular hemoglobin concentration38g/dl0.12650.4MMO:0000295blood hemoglobin analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107841DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood hemoglobin amounthemoglobin, MCH, MCHCRS:0001789BDIX/CrCrlmale92 days10CMO:0000291mean corpuscular hemoglobin concentration37g/dl0.18970.6MMO:0000295blood hemoglobin analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107843DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte size traitMCV, RDW%RS:0001789BDIX/CrCrlmale71 days10CMO:0000041red blood cell distribution width-coefficient of variation16.9%0.22140.7MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107846DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte size traitMCV, RDW%RS:0001789BDIX/CrCrlmale92 days10CMO:0000041red blood cell distribution width-coefficient of variation17.7%0.12650.4MMO:0000174automated hematology analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107848DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.lymphocyte quantityLYMRS:0001789BDIX/CrCrlmale71 days10CMO:0000371blood lymphocyte count to total leukocyte count ratio8.1%0.2530.8MMO:0000145automated differential white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107851DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.lymphocyte quantityLYMRS:0001789BDIX/CrCrlmale92 days10CMO:0000371blood lymphocyte count to total leukocyte count ratio8%0.09490.3MMO:0000145automated differential white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107853DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood triglyceride amountserum triglyceride levelRS:0001789BDIX/CrCrlmale71 days10CMO:0000360serum triglyceride level265mg/dl8.221926.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107897DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood aspartate transaminase amountserum aspartate aminotransferaseRS:0001789BDIX/CrCrlmale71 days10CMO:0000581serum aspartate aminotransferase activity level139U/l2.59318.2MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107902DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood aspartate transaminase amountserum aspartate aminotransferaseRS:0001789BDIX/CrCrlmale92 days10CMO:0000581serum aspartate aminotransferase activity level193U/l8.221926.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107904DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.blood amylase amountserum amylaseRS:0001789BDIX/CrCrlmale92 days10CMO:0003519serum amylase activity level3190U/l77.1596244.0MMO:0000554automated serum analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107946DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003188heart right ventricle weight to tibia length ratio4.51mg/mm0.220.5821MMO:0000005post excision weight measurement0.0vehicle control condition106610vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003188heart right ventricle weight to tibia length ratio4.33mg/mm0.973.0674MMO:0000005post excision weight measurement0.0vehicle control condition106611vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left ventricle massRS:0000811SS/JrHsdMcwimale56 days7CMO:0002787heart left ventricle weight to tibia length ratio0.178g/cm0.00690.0183MMO:0000005post excision weight measurement0.0vehicle control condition106614vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left ventricle massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0002787heart left ventricle weight to tibia length ratio0.177g/cm0.00270.0085MMO:0000005post excision weight measurement0.0vehicle control condition106615vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.lung massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003144lung weight to tibia length ratio0.291g/cm0.04550.1204MMO:0000005post excision weight measurement0.0vehicle control condition106618vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.lung massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003144lung weight to tibia length ratio0.33g/cm0.0040.0126MMO:0000005post excision weight measurement0.0vehicle control condition106619vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003192heart right atrium weight to tibia length ratio0.44mg/mm0.0360.0952MMO:0000005post excision weight measurement0.0vehicle control condition106622vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart right atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003192heart right atrium weight to tibia length ratio0.41mg/mm0.030.0949MMO:0000005post excision weight measurement0.0vehicle control condition106623vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left atrium massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003193heart left atrium weight to tibia length ratio0.41mg/mm0.020.0529MMO:0000005post excision weight measurement0.0vehicle control condition106626vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.heart left atrium massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003193heart left atrium weight to tibia length ratio0.45mg/mm0.030.0949MMO:0000005post excision weight measurement0.0vehicle control condition106627vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.liver massRS:0000811SS/JrHsdMcwimale56 days7CMO:0002995liver weight to tibia length ratio29.2mg/mm1.283.3866MMO:0000005post excision weight measurement0.0vehicle control condition106630vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.liver massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0002995liver weight to tibia length ratio29.1mg/mm0.662.0871MMO:0000005post excision weight measurement0.0vehicle control condition106631vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.kidney massRS:0000811SS/JrHsdMcwimale56 days7CMO:0003145single kidney weight to tibia length ratio0.0586g/cm0.00180.0048MMO:0000005post excision weight measurement0.0vehicle control condition106634vehicle control condition
3032Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.kidney massRS:0001480SS-Sod3m1Mcwimale56 days10CMO:0003145single kidney weight to tibia length ratio0.0556g/cm0.00110.0035MMO:0000005post excision weight measurement0.0vehicle control condition106635vehicle control condition
2339Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.hippocampus neuron quantityRS:0003328SS/NEisSlcnot specified547 days10CMO:0000328neuron count1258cells/mm232.0101.1929MMO:0000561ex vivo light microscopy with histochemistry0.0vehicle control condition (for 547.5 days)107465vehicle control condition (for 547.5 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney massRS:0000742WKYmale0 days11CMO:0001954left kidney wet weight to body weight ratio3.9mg/g0.10.3317MMO:0000005post excision weight measurement0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107455unilateral nephrectomy (for 150 days)vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.kidney glomerulus size traitRS:0000742WKYmale0 days11CMO:0003488kidney glomerular surface areakidney glomerulus surface area (CMO:0003488)12.6x 10E3 um23.812.6032MMO:0000561ex vivo light microscopy with histochemistry0.0unx150daysunilateral nephrectomy (for 150 days) then vehicle control condition107460unilateral nephrectomy (for 150 days)vehicle control condition
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.granulocyte quantityRS:0001789BDIX/CrCrlmale71 days10CMO:0000367blood granulocyte count to total leukocyte count ratio1.2%0.00.0MMO:0000145automated differential white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107856DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.granulocyte quantityRS:0001789BDIX/CrCrlmale92 days10CMO:0000367blood granulocyte count to total leukocyte count ratio0.8%0.00.0MMO:0000145automated differential white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107858DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.lymphocyte quantityLYMRS:0001789BDIX/CrCrlmale71 days10CMO:0000031blood lymphocyte count62.8x 1000 cells/ul0.31621.0MMO:0000145automated differential white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107861DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.lymphocyte quantityLYMRS:0001789BDIX/CrCrlmale92 days10CMO:0000031blood lymphocyte count77.7x 1000 cells/ul0.63252.0MMO:0000145automated differential white blood cell count test0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107863DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.xenobiotic metabolism traitRS:0002538SHRSP/A3NCrlmale175 days to 161 days6CMO:0003440time to peak measurement of Gd-DTPA uptake by kidney cortex5 seconds x 10 measurements averaged x 8 regions14.3s1.217.98MMO:0000718Dynamic Contrast-Enhanced Magnetic Resonance Imagingcortex of kidney400.05 seconds x 10 measurements averaged x 8 regionscontrolled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days)107374controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (for 35 days)
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.glomerular filtration traitRS:0002538SHRSP/A3NCrlmale175 days to 161 days6CMO:0003631multiregional glomerular filtration rate indexdCm/dt = KclCc(t)glomerular filtration rate index2.25mmol/min0.140.3429MMO:0000718Dynamic Contrast-Enhanced Magnetic Resonance Imaging400.05 sec x 10 measurements x 8 regionscontrolled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (between 35 and 63 days)107379controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (between 35 and 63 days)
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.body massRS:0002538SHRSP/A3NCrlmale175 days to 161 days6CMO:0000012body weight307g8.019.5959MMO:0000016body weighing method0.0controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days)107382controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (for 35 days)
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.arterial blood pressure traitRS:0002538SHRSP/A3NCrlmale175 days to 161 days6CMO:0000004systolic blood pressure162mmHg4.09.798MMO:0000031tail cuff plethysmography0.0controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days)107385controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (for 35 days)
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.glomerular filtration traitRS:0002538SHRSP/A3NCrlmale175 days to 161 days6CMO:0000765creatinine clearance2ml/min0.20.4899MMO:0000275urine creatinine analysis0.0controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days)107388controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (for 35 days)
3083Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.blood urea nitrogen amountRS:0002538SHRSP/A3NCrlmale175 days to 161 days6CMO:0000049blood urea nitrogen level20.5mg/dl5.814.207MMO:0000253blood urea nitrogen analysis0.0controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days)107391controlled sodium chloride content drinking water (1 %) (for 91 days)controlled fat content diet (24.5 %) (for 91 days)vehicle control condition (for 35 days)
3154Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.cone electrophysiology traitRS:0000655RCS-p+/LavRrrcnot specified119 days7CMO:0003702photopic B wave amplitude of ERG waveform23.1uV1.02.6458MMO:0000616electroretinographycornea0.0intravitrial injection98daysvehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) 109739vehicle control condition (2 ul) visible light stimulus (25 cd x s/m2)
3154Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.eye physiology traitRS:0000655RCS-p+/LavRrrcnot specified119 days7CMO:0003729optokinetic reflex6s0.270.7144MMO:0000754optokinetic reflex test method60.0intravitrial injection98daysvehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) 109741vehicle control condition (2 ul) visible light stimulus (25 cd x s/m2)
3157Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.rod electrophysiology traitRS:0000660RCS/LavRrrcnot specified35 days4CMO:0003705scotopic B wave amplitude of ERG waveform95.22uV16.1932.38MMO:0000616electroretinographyretina0.0pbs vehicle injection14daysvehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus109856vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours)visible light stimulus
3157Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.rod electrophysiology traitRS:0000660RCS/LavRrrcnot specified77 days4CMO:0003705scotopic B wave amplitude of ERG waveform13.01uV1.8453.69MMO:0000616electroretinographyretina0.0pbs vehicle injection56daysvehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus109862vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours)visible light stimulus
3157Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.rod electrophysiology traitRS:0000660RCS/LavRrrcnot specified49 days4CMO:0003705scotopic B wave amplitude of ERG waveform29.44uV7.43514.87MMO:0000616electroretinographyretina0.0pbs vehicle injection28daysvehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus109859vehicle control condition (2 ul) controlled exposure to darkness (for 12 hours)visible light stimulus
3155van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50.hypodermis integrity traitRS:0004900LOU/MWslmale130 days8CMO:0003700subcutaneous tumor diameter measurement37.2mm1.13143.2MMO:0000159in vivo caliper methodhindlimb0.0mean of 3 measurements28daysrat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) then vehicle control condition (1 ml/kg) (for 28 days)109745rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days)vehicle control condition (1 ml/kg) (for 28 days)
3155van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50.blood albumin amountRS:0004900LOU/MWslmale109 days5CMO:0000550serum albumin level219g/dl13.863631.0MMO:0000100gel electrophoresis0.0rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) then vehicle control condition (1 ml/kg) (for 7 days)109761rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days)vehicle control condition (1 ml/kg) (for 7 days)